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Factor Va Directs Catalysis by Factor Xa During Prothrombin 
Activation 
MICHAEL A. BUKYS 
Abstract 
Hemostasis occurs through the controlled activation and inactivation of clotting 
factors resulting in the arrest of bleeding without blockage to the vasculature, while 
thrombosis is the undesired formation of vascular blood clots, which adversely affects 
millions of people annually. Clotting factors circulate in blood as inactive zymogens, 
which are proteolytically activated in response to vascular injury, assembled into 
enzymatic complexes and in turn activate additional coagulation factors culminating in 
the production of thrombin from the enzymatic complex prothrombinase. The 
prothrombinase complex is composed of the activated enzymatic component factor Xa 
(fXa) complexed to the activated cofactor portion factor Va (fVa) assembled on a 
membrane surface in the presence of calcium. Prothrombinase enzymatic activity results 
in the conversion of prothrombin, the inactive precursor, to thrombin, the active enzyme 
following two sequential proteolytic cleavages. Thrombin in turn converts fibrinogen, a 
soluble precursor, to fibrin, the insoluble product which composes the meshwork of a 
fibrin clot. Therefore, the regulation of prothrombinase will result in the inhibition of clot 
formation.       
Incorporation of fVa into the prothrombinase complex increases the catalytic rate of 
fXa by five orders of magnitude and increasing kinetic studies have suggested that 
prothrombinase has two equilibrating forms which function in conjunction in the 
production of thrombin. The prothrombinase complex is unique in its function of 
v 
 
activating thrombin making it the ideal enzyme to target for regulating thrombin 
production, however the molecular events governing prothrombinase assembly and 
function are not well understood, and a better understanding of these events will provide 
novel targets for therapeutic compounds capable of regulating thrombin production. The 
long-term goal of this study is to determine the molecular interactions governing 
prothrombinase assembly/function, because the specific inhibition of thrombin formation 
will be realized through the disruption of prothrombinase assembly. Our central 
hypothesis is that discrete amino acid binding motifs present on fVa for the components 
of prothrombinase represent a potential source of anticoagulant molecules. Thus, defining 
binding regions present on fVa for fXa and or prothrombin is necessary in the 
development of specific inhibitors of prothrombinase that could be used in treatment of 
individuals with thrombotic tendencies. This proposal plans to define regions present in 
fVa to target disruption of prothrombinase assembly by addressing the following specific 
aims. 
Specific Aim 1: Determine the relative contribution of the binding of fVa’s heavy 
chain to fXa in the overall function of prothrombinase. 
Specific Aim 2: Determine the role of the carboxyl-terminal portion of the heavy 
chain of fVa in prothrombinase catalyzed activation of prothrombin. 
Specific Aim 3: Determine the discrete amino acid residue(s)/region(s) present in the 
light chain of fVa which are involved in the recognition of fXa.  
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CHAPTER I 
INTRODUCTION 
One of the most important systems within the human body is the vasculature, 
because all organs and tissues are dependent on it for survival. Blood transports all of the 
nutrients and removes all of the metabolic wastes from the tissues of the body. Therefore 
maintenance of the vascular system, termed hemostasis, is vital for survival. Hemostasis 
is the controlled arrest of bleeding and maintains vessel integrity with minimal blood loss. 
Hemostasis ensures the balance between the opposing undesired conditions of thrombosis 
and hemophilia. Thrombosis is the unneeded formation of a clot within the vasculature 
and can result in deep vein thrombosis (DVT), pulmonary embolism, stroke or heart 
attack (1). Hemophilia is uncontrolled bleeding and results in severe blood loss. Both 
thrombosis and hemophilia have contributing genetic components as well as acquired 
causes and better treatment methods are needed for both of these conditions.   
The entire vasculature is lined with a single layer of endothelial cells which form 
the walls of the vessels and veins which normally function as an anticoagulant surface 
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ensuring no blockage to the vasculature occurs (2). An injury occurs when the endothelial 
lining of the vasculature is disrupted allowing the circulating blood to leak outside of the 
vasculature resulting in the blood being exposed to the sub-endothelial environment. The 
sub-endothelial environment has many procoagulant components within it which function 
to promote clot formation (3). Of these procoagulant factors collagen and the protein 
tissue factor are essential. Exposure of the blood to collagen results in the activation of 
platelets and exposure of the blood to tissue factor initiates the coagulation response (4,5).  
An injury to the vasculature triggers many other responses all of which result in blockage 
of the injured site as a means to minimize blood loss. The combination of all of these 
responses is termed hemostasis and is divided into two interconnecting processes termed 
primary and secondary hemostasis. 
1.1 PRIMARY HEMOSTASIS 
The initial response to vascular injury is termed primary hemostasis. Primary 
hemostasis involves two interrelated processes; first a narrowing of the injured vessel 
minimizes blood flow to the damaged area while the formation of an initial platelet plug 
seals the injured site (6). Vasoconstriction is the first response to an injury that occurs in 
a damaged blood vessel and is a narrowing of the vessel to restrict blood flow to the 
injured area resulting in a minimization of blood loss. Exposure of blood to the sub-
endothelial environment causes platelets to adhere at the injured site resulting in the 
formation of a primary platelet plug. Exposure of platelets to the collagen present in the 
sub-endothelial environment stimulates the activation of platelets (7).  
Activated platelets release the contents from their interior alpha and dense granules 
resulting in the secretion of the vasoconstrictors serotonin, prostaglandin and 
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thromboxane (8). An enzymatic flipping of inner leaflet phosphatidylserine phospholipids 
to the outer leaflet upon activation of platelets creates an enzymatic surface capable of 
sustaining the formation of enzymatic complexes composed of coagulation factors which 
are attracted to the negatively charged surface (9,10). The activation of platelets also 
results in the release of many molecules from within the platelet needed for clot 
formation, including fibrinogen, factor V and von Willebrand factor (11). All sub-
endothelial tissues express the cellular membrane protein tissue factor which is exposed 
to the circulation when the endothelial layer is disrupted. The exposure of tissue factor to 
the circulation is the initiating event in the coagulation portion of hemostasis, termed 
secondary hemostasis (9,10). The initial platelet plug is a temporary blockage to the site 
of injury and is strengthened by the deposition of fibrin, the end product of the 
coagulation cascade. The polymerization of fibrin leads to the stabilization of the platelet 
plug needed to ensure hemostasis. 
1.2 COAGULATION RESPONSE 
Secondary hemostasis is also referred to as the coagulation cascade and culminates in 
the formation of fibrin deposition upon the initial platelet plug resulting in a stabile 
blockage to the injured site (12, 13). Platelets are actively involved in the coagulation 
response known as secondary hemostasis because they generate the negatively charged 
catalytic surface needed for formation of all enzymatic complexes (3). The coagulation 
cascade is composed of the sequential activation of clotting factors culminating in the 
production of fibrin from the zymogen fibrinogen. Coagulation enzymes are serine 
proteases with highly specific substrate recognition determined by exosites distant from 
their active sites (14). Coagulation factors circulate in inactive forms that are 
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proteolytically activated in response to vascular injuries. Activated clotting factors 
assemble into sequential enzymatic complexes on the membrane surfaces provided by 
activated platelets (9,10,15). The association between activated membrane surfaces and 
the components of the enzymatic complexes are dependent on Gla domains. Gla domains 
are regions present within the proteins that have several gamma carboxylated glutamic 
acid residues (16). The gamma carboxylation of glutamic acid residues are vitamin K 
dependent post-translational modifications necessary for protease recognition of the 
membrane surface. 
The initiating event in the coagulation cascade is the exposure of tissue factor to the 
circulation resulting in the formation of the extrinsic Xase complex (17). A small fraction 
of fVII circulates in an active form and will complex with tissue factor when it is exposed 
to the blood (9). The extrinsic Xase complex is formed when circulating factor VIIa 
comes in contact with tissue factor. The extrinsic Xase complex recognizes the substrates 
factor IX and factor X proteolytically converting them to their active forms factor IXa 
(fIXa) and factor Xa (fXa), respectively (18). However the extrinsic Xase complex 
recognizes the substrate fIX with a much higher affinity than it recognizes fX and 
consequently the production of fIXa is necessary, needed for formation of the intrinsic 
Xase complex, is necessary for efficient production of fXa.  
The intrinsic Xase complex is formed when the enzymatic component fIXa, generated 
from the extrinsic Xase complex, comes in contact with its activated cofactor portion, 
factor VIIIa, on a catalytic surface provided by activated platelets (19). The importance 
of the intrinsic Xase complex in proper fibrin formation is demonstrated by the genetic 
disorder hemophilia which occurs in individuals missing the gene for fVIII. The intrinsic 
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Xase complex recognizes the substrate fX, with a far greater specificity than the extrinsic 
Xase complex and is thus obligatory for sufficient generation of the active form of fX and 
consequently normal fibrin formation. Formation of the intrinsic Xase complex results in 
the rapid generation of fXa, the enzymatic component of the prothrombinase complex 
which is responsible for the activation of prothrombin to its active form thrombin. 
The prothrombinase complex is composed of the activated enzymatic component, fXa, 
associated with the activated cofactor portion, factor Va (fVa), on a catalytic surface 
supplied by activated platelets in the presence of calcium ions (20,21). Prothrombinase 
proteolytically activates prothrombin through two sequential activating cleavages at 
Arg
320
 and Arg
271
 to produce the enzyme product, thrombin. Thrombin is responsible for 
the conversion of fibrinogen, the soluble precursor, to fibrin the insoluble monomer 
which composes the meshwork that stabilizes the fibrin clot. 
1.3 THROMBIN REGULATES ITS OWN PRODUCTION    
 Thrombin recognizes its substrates through exosites, these are regions exposed to 
plasma in the activate form of thrombin which are composed of extended basic amino 
acid residues that facilitate substrate recognition (22,23). Thrombin has several substrates 
which are recognized by its two anion binding exosites referred to as ABE I and ABE II. 
Thrombin interacts with the substrates thrombomodulin, fibrinogen, heparin cofactor II, 
PAR1, and the hirudin peptides through ABE I, while ABE II is involved in the 
recognition by thrombin with the substrates heparin cofactor II, protease nexin and 
antithrombin III. Both ABE I and ABE II have been implicated in interacting with the 
cofactors for the intrinsic Xase complex and the prothrombinase complex, fV and fVIII 
respectively (24).   
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The initial production of thrombin up-regulates thrombin production by activating 
the cofactors needed for the intrinsic Xase and the prothrombinase complexes, fVIII and 
fV respectively (25-27). The proteolytic activation of these zymogen cofactors by 
thrombin results in greatly increasing thrombin production, because the active cofactors 
greatly up-regulates the activity of the intrinsic Xase and the prothrombinase complexes. 
The increased fVIII generated for the intrinsic Xase complex results in a greatly 
increased fXa production coupled with a greatly increased fVa production produces a 
surge in the concentration of the prothrombinase complex and consequently greatly 
accelerates thrombin generation. Thrombin is the enzyme responsible for the conversion 
of fibrinogen, the inactive soluble zymogen, to fibrin, the insoluble meshwork of the 
fibrin clot. Once formed fibrin is attracted to the platelet plug mediated through platelet 
receptors and polymerizes resulting in the strengthen platelet plug. An additional way 
that thrombin is responsible for greatly accelerating a fibrin clot formation is by the 
activation of factor XIII. The active form of fVIII, fXIIIa, functions in cross linking the 
fibrin monomers that are deposited on the platelet plug as an additional way of stabilizing 
the fibrin clot (9).  
The fact that thrombin also down-regulates the coagulation response by the 
proteolytic activation of protein C (PC) shows the tight regulation of the coagulation 
cascade. The active form of protein C (APC) is involved in down regulating thrombin 
production by the enzymatic degradation of the cofactors involved in the intrinsic Xase 
and prothrombinase complexes, fVIIIa and fVa respectively (28). As thrombin is 
generated it will complex with thrombomodulin, a protein present on the surface of the 
endothelial lining of the vasculature, resulting in the formation of the APCase enzymatic 
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complex (29,30). The APCase complex is responsible for the activation of PC. Once 
generated APC down regulates thrombin production through the proteolytic degradation 
of fVIIIa through three sequential cleavages at Arg
336
, Arg
562
 and Arg
740
 resulting in the 
loss of the intrinsic Xase complex ability to generate fXa. The enzymatic degradation of 
fVa is also mediated by APC through three sequential proteolytic cleavages of fVa at 
Arg
506
, Arg
306
, and Arg
679
 destroying the affinity of fVa for the prothrombinase complex.         
1.4 PROTHROMBINASE REGULATES THROMBIN PRODUCTION 
As previously described coagulation occurs by a series of limited enzymatic 
cleavages    of    sequential   clotting   factors   calumniating   in   the   formation   of   the 
prothrombinase complex (20,21). Both the intrinsic and extrinsic pathways lead to the 
formation of the prothrombinase complex, also known as the common pathway because 
of its central role in thrombin production. Prothrombinase is unique in its function of 
activating prothrombin to generate thrombin. The prothrombinase complex consists of an 
assembly of activated clotting factor X (fXa) and activated clotting factor V (fVa) on a 
platelet surface in the presence of calcium ions (20,21). Factor Xa is the enzymatic 
portion of prothrombinase and is capable of catalyzing prothrombin activation by initially 
cleaving Arg
271
 producing the two inactive intermediates, prethrombin 2 (residues 272-
579), and fragment 1·2 (residues 1-271) (31). Prethrombin 2 is sequentially cleaved by 
membrane-bound fXa at Arg
320
 to produce thrombin. This process proceeds through 
inactive intermediates and has an overall reaction rate insufficient for timely thrombin 
production.  
The association of fVa with fXa in the prothrombinase complex causes a reversal of 
the observed cleavage pattern of prothrombin in addition to a 300,000 fold increase in the  
 8 
 
S S 
 NH2- 
 
S S 
 A chain B chain 
 
 
Fragment 1·2 -Thrombin 
 S S 
Arg
271 
Fragment 1·2 Prethrombin 2 
Factor Xa 
Membrane 
 S S 
Arg
320 
Meizothrombin 
Factor Xa/Va 
Membrane 
-COOH 
Prothrombin 
Arg
155 Arg284 
Pathway I Pathway II 
Figure 1.1 – The activation of prothrombin. Pathway 1 - Membrane-bound fXa 
catalyzes prothrombin activation by initially cleaving at Arg
271
 producing the inactive 
intermediate prethrombin 2 and fragment 1·2. Prethrombin 2 is then sequentially 
cleaved at Arg
320
 to produce thrombin and fragment 1·2. Pathway 2 – In the presence 
of a fully assembled prothrombinase complex the rate of thrombin generation is 
greatly enhanced and the order of the prothrombin activating cleavages are reversed. 
Prothrombinase initially cleaves prothrombin at Arg
320
 generating the active 
enzymatic intermediate, meizothrombin. Meizothrombin is then cleaved at Arg
271
 to 
produce thrombin and fragment 1·2. 
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rate of thrombin production. Prothrombinase catalyzed activation of prothrombin 
proceeds through initially cleaving prothrombin after Arg
320
, producing meizothrombin 
(residues 1-320 covalently attached through disulfide linkage to residues 321-579), an 
enzymatic active intermediate (32). Prothrombinase rapidly consumes the meizothrombin 
intermediate by catalyzing the additional activating cleavage at Arg
271
 producing 
thrombin and fragment 1·2 (33,34). In addition to the greatly accelerated rate of thrombin 
generation realized through prothrombinase as compared to membrane-bound fXa, the 
enzymatic intermediate meizothrombin is capable of activating additional clotting factors.  
1.5 FACTOR Va INTERACTS WITH ALL COMPONENTS OF 
PROTHROMBINASE 
The physiological importance of fVa is demonstrated by the increased cases of DVT 
attributed to a single point mutation in its gene and the fact that its loss results in severe 
hemophilia. The zymogen factor V (fV) has a MW of 330,000kDa and circulates through 
plasma at a concentration of 20nM. FV is composed of three homologous A domains; the 
A1 domain composed of residues 1-303, the A2 domain composed of residues 317-656 
and the A3 domain composed of residues 1546-1877, an interconnecting B region 
composed of residues 710-1545 and two C domains; the C1 domain composed of 
residues 1878-2036 and the C2 domain composed of residues 2037-2196 (35). The 
zymogen fV has the domain composition of A1-A2-B-C1-C2-A3 and zymogen activation 
is realized through the removal of the interconnecting B-domain from the rest of the 
molecule. Both thrombin and meizothrombin activate fV through three sequential 
cleavages occurring after Arg
709
, Arg
1018
 and Arg
1545
 resulting in an active cofactor, fVa,  
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C1 C2 COOH NH2 NH2 COOH 
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2+ 
A1 A3 A2 
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B 
Figure 1.2 – The activation of the zymogen factor V occurs through three sequential 
thrombin mediated cleavages occurring at Arg
709
, Arg
1018
 and Arg
1545
 resulting in the 
active form of the cofactor composed of a heavy chain derived from the carboxyl-
terminal portion and a light chain derived from the amino-terminal portion. The 
heavy chain is composed of residues 1-709 while the light chain is composed of 
residues 1546-2196 and the two chains are associated with each other through 
calcium ions.     
 
 
 
 
 
 
 
 
Figure 1.2 
 
 
 
 
 
 
 
 
 11 
composed of an amino-terminal derived heavy chain (residues 1-709) of Mr 105,000kDa 
and a carboxyl-terminal  derived  light  chain (1546-2196)  of  a  Mr  of  74,000kDa.  The 
association of the heavy and light chains of fVa is non-covalent and dependent on the 
presence of Ca
2+
 ions (36).  
Both the heavy and light chains of fVa are needed in binding the components of the 
prothrombinase complex. The heavy chain of fVa interacts with prothrombin through an 
acidic region present at the carboxyl-terminal portion (37,38). The heavy chain of fVa is 
also involved in recognition of fXa through residues present within the A2 domain at 
positions 323-331 (39,40). It has been demonstrated that the light chain of the cofactor 
binds both the membrane surface and fXa. The recognition of the membrane surface by 
the light chain of fVa occurs through residues present within the C2 domain and has been 
thoroughly characterized (41-43). Previous studies have implicated the A3 domain of the 
light chain of fVa in binding fXa, however little is known on which amino acid residues 
are involved in the association (44-45).  
1.6 THE INACTIVATION OF FVa  
 Due to the central role fVa plays in thrombin generation both the generation and 
degradation of fVa is highly regulated and the existence of the active form of fV is very 
transient because it is degraded shortly after it is generated. Thrombin not only up-
regulates fVa production, but starts the down regulation of fVa by activating protein C 
(PC) the serine protease responsible for the enzymatic degradation of fVa (46). PC 
circulates in plasma at a concentration of 60nM and is activated by an enzymatic complex 
composed of thrombin and thrombomodulin (47). The activation of PC occurs through a 
single proteolytic cleavage occurring at Arg
169
 to produce the active form, APC. APC 
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down regulates thrombin production by inactivating the cofactor fVa through three 
sequential cleavages occurring at Arg
506
, Arg
306
 and Arg
679
 (28).  
The importance of APC for the down regulation of thrombin production is 
illustrated through the commonly occurring fV
LEIDEN
 mutation. The fV
LEIDEN
 mutation 
has been correlated to an increased occurrence of DVT and results from a single point 
mutation in the gene encoding fV which causes a R506Q substitution in the protein (48). 
This substitution removes the APC mediated cleavage site within the A2 domain of fVa 
and consequently decreases the rate of APC mediated inactivation of fVa 10-fold (49). 
Increased occurrence of DVT is associated with the decreased ability of APC to degrade 
the active form of the fV
LEIDEN
 mutation.  
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CHAPTER II  
INCORPORATION OF FACTOR Va INTO PROTHROMBINASE IS REQUIRED 
FOR COORDINATED CLEAVAGE OF PROTHROMBIN BY FACTOR Xa   
2.1 ABSTRACT 
The interaction of fXa with fVa promotes prothrombinase assembly and is governed 
by two distinct regions within fVa. It has been demonstrated on several occasions that 
one important region governing the fXa/fVa interaction and proper prothrombinase 
assembly is present within the A2 domain of the heavy chain of fVa. We have used 
overlapping synthetic peptides representative of residues 307-348 of the A2 domain to 
screen their ability to inhibit prothrombinase activity in a fXa dependent manner. Peptide 
studies indicated amino acid residues 323, 324, 330 and 331 of the A2 domain are crucial 
for fVa recognition of fXa. The present study employs recombinant mutations within 
these residues consisting of 
323
DY
324
  323FF324 (fVaFF), 330DV331  330MI331 (fVaMI) and 
the combined mutation of 
323
DY
324 
and 
330
DV
331
  323FF324 and 330MI331 (fVaFF/MI). All 
recombinant molecules were assayed for their ability to accelerate fibrin clot formation in 
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clotting based assays. Kinetic studies determined Kd values for the fVa/fXa interaction 
showing an approximate 4-5 fold decrease for the ability of fXa to interact with rfVa
FF
 
and rfVa
MI
 and an approximate 50-fold decrease in the ability of fXa to interact with the 
rfVa
FF/MI
 mutant. Determined Kcat values generated for prothrombinase catalyzed 
reactions performed with fXa fully saturated with the rfVa
MI
 and rfVa
FF
 mutants 
demonstrated values comparable to rfVa
WT
. While prothrombinase assembled with the 
combined rfVa
FF/MI
 mutant demonstrated a severely decreased Kcat value when 
compared to rfVa
WT
. The present study demonstrated drastic changes in the kinetic 
parameters governing prothrombinase assembled with the rfVa
FF/MI
 molecule 
demonstrating the effects the loss of the fXa/fVa interaction has on the normal function 
of prothrombinase. 
2.2 INTRODUCTION 
 The arrest of bleeding is dependent on the generation of thrombin from the 
enzymatic complex prothrombinase (1-3). Though the enzymatic component of 
prothrombinase, activated factor X (fXa) is capable of activating the zymogen 
prothrombin, the rate of this reaction is insufficient for timely thrombin generation in 
response to vascular injury. The incorporation of activated factor V (fVa) into the 
prothrombinase complex accelerates the rate of thrombin generation by five orders of 
magnitude, as well as reverses the order of the two activating cleavages that occur within 
prothrombin (3,4). It has been well-established that membrane-bound fXa initially 
cleaves prothrombin at Arg
271
 resulting in a non-enzymatic intermediate, prethrombin 2 
(residues 271-579 of prothrombin) which is then subsequently cleaved at Arg
320
 to 
generate thrombin (4). The association of fXa with fVa, results in a reversal of these two 
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proteolytic events with initial prothrombin cleavage occurring at Arg
320
 followed by 
cleavage at Arg
271
 (3,5) This latter pathway to thrombin generation has an enzymatic 
intermediate, meizothrombin, and occurs at a greatly accelerated rate (6).  
 The zymogen factor V (fV) circulates in plasma at a concentration 20nM and has 
no cofactor effect before proteolytic processing resulting in the formation of the active 
form of fV. Both thrombin and fXa are capable of activating fV through three sequential 
cleavages occurring at Arg
709
, Arg
1018
 and Arg
1545
 generating an amino-terminally 
derived heavy chain composed of two homologous A domains (A1-A2), a carboxyl-
terminally derived light chain composed of an A domain followed by two C domains 
(A3-C1-C2) and the release of the interconnecting B domain (7,8). The association of the 
heavy and light chains of fVa is calcium dependent and necessary for the generation of a 
functional cofactor (9). The association of fVa with fXa is highly specific with a Kd of 
approximately 0.2nM and has been shown to be mediated through two distinct regions 
present within the A2 and A3 domains of fVa (9).             
Experimental evidence for the A2 domain’s involvement in recognition of fXa 
has been demonstrated by many research groups. Experiments employing activated 
protein C (APC), an anticoagulant molecule which degrades the heavy chain of fVa, 
correlates the loss of the cofactor effect to the removal of the A2 domain from fVa 
(10,11). APC degrades fVa through three consecutive cleavages occurring within the 
heavy chain of fVa at Arg
506
, Arg
306
 and Arg
679
 and completely inactivates the cofactor. 
Peptide studies of the A2 domain have shown that N42R (a synthetic peptide designed 
with the corresponding sequence from amino acid residues 307-348 of the heavy chain of 
fVa) is capable of mimicking the loss of function associated with APC degradation of 
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fVa by strongly inhibiting prothrombinase activity in a fXa dependent manner (11). 
Further peptide studies have indicated that residues 323-324 and 330-331 from fVa are 
involved in binding fXa and are required for optimal cofactor effect for the 
prothrombinase catalyzed activation of prothrombin (12,13). The present recombinant 
study was undertaken to identify the contribution of these residues to the overall function 
of the prothrombinase molecule.  
2.3 EXPERIMENTAL PROCEDURES 
 Materials, Reagents and Proteins. L--phosphatidylserine (PS) and L--
phosphatidylcholine (PC) were purchased from Avanti Polar Lipids (Alabaster, AL) and 
prepared as previously described (14) and quantified by assaying for phosphorus. The 
chromogenic substrate Spectrozyme-TH was purchased from America Diagnostica, Inc 
(Greenwich, CT). Human -thrombin, prothrombin, human fXa and the fluorescent 
thrombin inhibitor dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (Dapa) were 
purchased from Hematologic Technologies, Inc. (Essex Junction, VT). The monoclonal 
antibody hFV1 coupled to Sepharose, and the two monoclonal antibodies against factor 
V (against the heavy and the light chains respectively, HFVHC#17 and HFVLC#9) were 
provided by Dr. Kenneth G. Mann (Department of Biochemistry, University of Vermont, 
Burlington, VT). Diisopropyl fluorophosphates (DFP), O-phenylenediamine 
dihydrochloride (OPD), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
Trizma, Coomassie Blue R-250 and factor V-deficient plasma were purchased from 
Sigma. Polyethylene glycol (Mr 8000) was purchased from J. T. Baker (Danvers MA). 
The secondary anti-mouse and anti-sheep IgG coupled to peroxidase were purchased 
from Southern Biotechnology Associates Inc. (Birmingham, AL). The chemiluminescent 
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reagent ECL
+
 was purchased from Amersham Biosciences. The thromboplastin reagent 
(recomboplastin) used in clotting assays was purchased from Beckman (Fullerton, CA). 
The cDNA encoding fV was purchased from American Type Tissue Collection (ATCC 
40515 pMT2-V, Manassas, VA). All restriction Enzymes were purchased from New 
England Biolabs (Beverly, MA). Human fV and fVa were purified and concentrated 
using methodologies previously described employing the monoclonal antibody hFV#1 
coupled to sepharose and heparin-sepharose respectively (11,15,16).  
 Generation of Recombinant Mutations. The recombinant fV mutations used 
throughout this series of experiments were generated using PCR based mutagenesis. The 
heavy chain mutations were generated using the primers 5'-
GAAGAGGTGGTTCTTCTTCATTGCTGC-3' (sense) and 5'-
GCAGCAATGAAGAAGGAACCACCTCTTGCTGC-3' (antisense) for the rfVa
FF
 
mutation, the primers 5'-CATTGCTGCAGAGATGATCATTTGGGACTATGC-3' (sense) 
and 5'-GCATAGTCCCAAATGATCATCTCTGCAGCAATG-3' (antisense) were used 
to generate the rfVa
MI
 mutation (the underlined portion of the primers are the mismatched 
bases). PCR reactions were performed in the presence of outer primers encompassing the 
upstream XcmI restriction site (5'-ACATCCACTACCGCAATATGAC-3') and the down 
stream Bsu361 site (5'-CCTCAGGCAGGAACAACACCATGA-3'). PCR products were 
purified from agarose gels and subjected to a third PCR reaction performed in the 
presence of the purified products. The product from the third PCR reaction and pMT2-fV 
were both subjected to XcmI and Bsu361 digestion followed by a ligation reaction to 
insert the desired mutations. Ligation products were transformed into chemically 
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competent bacteria cells and colonies were screened for the presence of the desired insert 
through DNA sequencing.  
 Generation of Recombinant Proteins. All of the respective mutagenic plasmids 
were transiently transformed into Cos 7 cells using the transformation reagent fugene 6. 
Cos 7 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100 
g/ml streptomycin, 100 IU/ml penicillin and incubated at 37°C in the presence of 5% 
CO2 atmosphere. Transfection was performed on plates approximately 70% confluent by 
the addition of 2 g of fugene 6 treated DNA per plate. Plates of transfected Cos 7 cells 
were incubated for 48 hours before being washed twice with a phosphate buffered saline 
solution followed by incubation in the presence of VP-SFM medium supplemented with 
5mM L-glutamine. Harvesting of the cultured VP-SFM medium was performed for 4 
consecutive 24 hour intervals and either concentrated or frozen for future use.  
 Quantification of Recombinant fV Molecules within the Harvested Medium. 
Harvested medium from the transfected Cos 7 cells were concentrated by centrifugation 
on YM-30 centricons to a final volume of approximately 1 ml followed by three 
consecutive washes with trizma buffered saline solution containing 5mM CaCl2. ELISA 
specific for fV was performed on the washed concentrated medium containing the fV 
heavy chain mutants. Briefly, 96-well plates were coated with a polyclonal anti-fV 
antibody diluted in a carbonate buffer and incubated overnight at 4°C, ELISA plates were 
then washed three times with a trizma buffered saline (TBS) solution containing 5% 
tween 80 followed by an hour incubation at 37°C  in the presence of 5% milk diluted in 
TBS + 5% tween 80. Serial dilution of the concentrated harvested medium containing the 
respective rfV heavy chain mutants were incubated along side a plasma derived fV serial 
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dilutions performed in triplicate with concentrations ranging from 0.01g to 10g as a 
standard. The monoclonal anti-human fV antibody, -hfV#17, was incubated on the 
washed ELISA plate at a concentration of 5g/ml for an hour at 37°C followed by an 
additional hour incubation of the ELISA plate in a 1:2000 dilution of a secondary anti-
mouse coupled with HRP antibody. ELISA plates were developed using OPD (5mg) 
tablets dissolved in 12ml 0.1M citric acid and 0.1M Na2HPO4 for 15 minutes before the 
addition of 150l of 2.5M H2SO4 to stop the reaction. The standard was graphed as log of 
the concentration of the plasma derived fV vs. the absorbance at 490nm. The absorbance 
of the serial dilutions of the concentrated medium was compared to that of the standard 
for the determination of the concentration of the respective rfV molecules.  
Activation of Recombinant Molecules. Throughout the research, activation of the 
respective recombinant molecules was accomplished by incubating the molecules with 
thrombin at a 1/100 (enzyme to substrate) ratio for ten minutes at 37°C. Addition of 2mM 
DFP, a specific serine protease inhibitor, was performed to stop the activation reaction 
followed by 10 minute incubation on ice before use. Experiments showed that these 
conditions assured complete activation of the cofactor with minimal thrombin 
degradation of the activated molecule. However, for all protein preparations western blots 
using monospecific antibodies recognizing the heavy and light chains of fVa respectively 
was performed to confirm the generation of the active cofactor. 
Assaying the Activity of the Recombinant Molecules. Equivalent concentrations of 
activated recombinant proteins were used in a discontinuous assay measuring thrombin 
production monitored through chromogenic substrate. Reaction mixtures were composed 
of 1.4M prothrombin being activated by 5nM fXa in the presence of 0.5nM fVa species, 
 27 
5M Dapa, 10M PCPS in a HEPES buffered saline solution containing 5mM CaCl2 at a 
pH of 7.40. Reactions were initiated by the addition of prothrombin and aliquots of the 
reaction mixture were removed at various time points during the first 5 minutes of the 
reaction and quenched in a two-fold volume of a HEPES buffer containing EDTA within 
a 96-well plate. Plates were then incubated with a final concentration of 0.4mM 
chromogenic substrate, Spectrozyme TH, for 15 minutes before optical density readings 
were taken at 405nm. Control reactions performed in the absence of fVa and with plasma 
derived fVa were performed to establish minimal and optimal parameters for this series 
of experiments. The reactions employing the recombinant proteins fVa
WT
, fVa
FF
, fVa
MI
 
and fVa
FF/MI
 were performed simultaneously with the control reactions to demonstrate 
that any decrease in prothrombinase activity was due to the mutations present in the 
fVa
FF
, fVa
MI
 and fVa
FF/MI
 molecules. Reactions with increased concentrations of fVa
FF
, 
fVa
MI
 and fVa
FF/MI
 molecules were performed to determine if normal prothrombinase 
function could be restored using higher concentrations of the respective recombinant 
mutant molecules. All reactions had aliquots removed from the mixture prior to initiation 
of the reaction to determine if any increase in absorption was due to the reaction mixture. 
All experiments were graphed mOD verses time (seconds) using Prism graphing software. 
Determination of Kinetic Parameters Governing Mutant Molecules – Assays 
measuring the kinetic parameters consisted of prothrombinase assembled in the presence 
of prothrombin and measured the appearance of thrombin by the secondary event of 
cleavage of a chromogenic substrate. This discontinuous assay was monitored at several 
time points within the first minute or two of the reaction. A limiting amount of fXa was 
titrated with increasing concentrations of fVa to determine the apparent Kd value for the 
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interaction. Titrations were performed in 96 well plates and measured the initial 
velocities of product formation from the different concentrations of the titrant (fVa). 
Time points of the different reactions were stopped by addition of EDTA. Prism graphing 
software was used to graph the data and generate apparent kd values for the titrations. In 
all cases mutants were compared to wild type and plasma derived fVa and measurements 
were done in triplicate with different protein purifications. The obtained kd values were 
used to determine proper ratios of the respective fVa mutants to fXa used in subsequent 
prothrombin titration reactions ensuring similar concentrations of the assembled 
prothrombinase complex were used. The degree of fXa saturation was calculated using 
equation 1 (17),  
[Eb] = ((i·[Tt] + [ET] + Kd) - √((i·[Tt] + [Et] + Kd)
2
 – 4i·[Tt]·[Et])))/2            (Eq. 1) 
where Eb is the percentage of bound enzyme, i is the stoichiometry between fXa and fVa 
(i.e., 1), Tt is the total concentration of the titrant (i.e., fVa), Et is the total concentration 
of the enzymatic component (i.e., fXa), and Kd is the observed disassociation constant 
determined from the respective fVa titration.         
Prothrombin titrations were performed to determine the apparent Km and Kcat 
values for the fully assembled enzymes. Prothrombin titrations were performed in 96 well 
plates and reactions consisted of limiting concentrations of fXa in the presence of 
saturating concentrations of fVa as determined by kd values obtained from the fVa 
titrations. Prism graphing software was used to determine measurements of the initial 
velocity of the varied prothrombin concentrations and used to generate a secondary graph 
measuring maximum velocity and km.   
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Effects of the Mutant fVa Molecules in the Activation of Prothrombin. – 
Monitoring prothrombin consumption using SDS PAGE allowed for the determination of 
prothrombin cleavage patterns. Prothrombinase assembled with the various fVa mutants 
was used in prothrombin activating reactions monitored through SDS-PAGE followed by 
coomassie blue staining. Aliquots of reaction mixtures at various time points were placed 
in 0.2M acetic acid to stop the reaction followed by preparation for SDS-PAGE as 
previously described (13).   
Measurement of Clotting Times – One stage and two stage clotting times were 
performed with all of the recombinant molecules at identical concentrations. One-stage 
clotting assay consisted of addition of the procofactor (fV) into fV deficient plasma, 
while two stage clotting assay consisted of the activated cofactor (fVa) being added to 
fV-deficient plasma. In both cases coagulation was initiated by the addition of the 
thromboplastin reagent and time to clot formation measured and transformed into specific 
activity. Deficiency in mutant molecules to accelerate fibrin clot formation in fV-
deficient plasma implies a functional defect. All purified protein preparations were 
assayed in triplicate by this manner. 
Measurement of the Interaction of the Two Mutation Sites – Since the point 
mutations generated in the recombinant fVa molecules decrease the stability of the 
enzymatic complex, prothrombinase, the change in the free energy of the system can be 
evaluated to determine weather the two sets of mutations (i.e., rfVa
MI
 and rfVa
FF
) 
energetically interact (18-20). The following general equation is used to define the 
change in prothrombinase function due to the mutations (state B) as compared to the wild 
type fVa molecule (state A), 
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  GB = GB - GA  (Eq. 2) 
Evaluation of each of the three recombinant mutants presented in this study was 
accomplished by comparison to the rfVa
WT
 using the following equation, 
GA B = - RT ln [(kcat/Km)B/( kcat/Km)A]                              (Eq. 3) 
where R is the universal gas constant (2 cal·K
-1
·mol
-1
), T is the temperature in Kelvin 
(298K), kcat is the turnover number, and Km is the Michaelis-Menton constant for 
prothrombinase assembled with the various recombinant fVa molecules. The free energy 
of the interaction between two mutations can be calculated with the following general 
equation, 
                              Gint = GA B/C – (GA B + GA C)                               (Eq. 4)                               
where the term A  B and A  C represent either of the two mutations (i.e., rfVaMI and 
rfVa
FF
), the term A  B/C represents the double mutant (i.e., rfVaMI/FF) and the term 
Gint reflects energy exchange between the individual amino acids being studied. A 
Gint > 0 implies that the two mutation sites interact with each other reducing the 
catalytic efficiency of the enzyme and a Gint < 0 implies that the two mutation sites 
interact with each other in a fashion that enhances the catalytic efficiency of the enzyme.       
2.4 RESULTS 
 Previous studies have indicated that binding of the heavy chain of fV to fXa 
involves residues 323, 324, 330 and 331. In order to determine the contribution of these 
residues to the activity of prothrombinase a recombinant study mutating these residues 
was undertaken. PCR based mutagenesis was performed, as described in the method 
section to generate the following mutants; rfVa
FF
 (
323
DY
324
  323FF324), rfVaMI (330DV331 
  330MI331)  and  the  combined  mutation  of  rfVaFF/MI  (323DY324, 330DV331  323FF324, 
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•
No mutation                                    factor Vawt 
•
E323  F and Y324F                    factor VaFF 
•
E330  M and V331  I             factor VaMI 
•
E323  F/Y324  F and E330  M/V331  I   factor VaFF/MI 
Figure 2.1 – Mutations created for determination of heavy chain binding. 
Previous studies using peptides representative of the heavy chain sequences of fVa 
were used to determine binding regions. Recombinant proteins mutated at amino acid 
residues indicated in binding of fXa were generated to further test the results 
generated using synthetic peptides. The four recombinant proteins used throughout 
this study were: rfVa
WT
 (no mutations), rfVa
FF
 (residues 
323
EY
324
  FF), rfVaMI 
(residues 
330
EV
331
  MI) and the combined mutant rfVaFF/MI (323EY324  FF and 
330
EV
331
  MI both within the same construct). 
Figure 2.1 
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330
MI
331
). Figure 1 shows a schematic outlining the mutations described above 
demonstrating the sites where the mutations were introduced. 
 To investigate the possibility that the introduced mutations had a detrimental 
effect on zymogen activation, SDS PAGE followed by Western blot was performed on all 
of the recombinant mutations. Figure 2 shows Western blotting of the activated 
recombinant molecules. Lane 1 is plasma derived fV that has been activated through 
incubation with thrombin and serves as a control sample demonstrating the relative 
positions of both the heavy and light chains of the cofactor. Lanes 3 – 6 are samples of 
the recombinant molecules used throughout the study after incubation with thrombin to 
generate their active forms, they are arranged rfVa
WT
, rfVa
FF
, rfVa
MI
 and rfVa
FF/MI
 
respectively. All of the recombinant molecules generated both heavy and light chains 
following thrombin mediated activation, though there was a light chain degradation 
product detected within all of them. 
 To assess the ability of the respective recombinant mutants to function as a 
cofactor, identical concentrations of the recombinant mutants (500pM) were assembled 
into a prothrombinase complex and assayed for their ability to generate thrombin. Figure 
3 demonstrates that identical concentrations of plasma derived fVa (open circles) and 
rfVa
WT
 (closed circles) both accelerate the ability of fXa to generate thrombin to the same 
degree showing that there is no functional defect in the wild type cofactor molecule. Both 
the rfVa
FF
 (inverse filled triangles) and the rfVa
MI
 (filled triangles) displayed diminished 
thrombin formation, though the prothrombinase assembled with rfVa
MI
 was more 
deficient in producing thrombin. Combining both mutations sites in the rfVa
FF/MI
, 
produced  a  cofactor  that  was greatly defective in promoting thrombin production when  
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Figure 2.2 – Western Blot of Recombinant Heavy Chain Mutations. Western 
blotting with two monoclonal antibodies was performed on all of the recombinant 
molecules used throughout this series of experiments. Lane 1 shows activated plasma 
derived fV, lane 3 shows rfVa
WT
, lane 4 shows rfVa
FF
, Lane 5 shows rfVa
MI
 and lane 6 
shows rfVa
FF/MI
. Arrows indicate position of the heavy and light chain of the active 
cofactor as well as a low molecular weight degradation product which occurred upon 
thrombin incubation of the various recombinant molecules.  
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Figure 2.3 
 
Figure 2.3 – Activity assays comparing recombinant fVa molecules. The cofactor 
activity of the various recombinant fVa molecules were assayed in the presence of 5nM 
fXa as described in the experimental procedures. The various reactions shown above 
are: filled circles, 500pM rfVa
WT
; open circles, 500pM plasma derived fVa; filled 
inversed triangles, 500pM rfVa
FF
; filled triangles, 500pM rfVa
MI
; open squares, 1nM 
rfVa
FF/MI
; open triangles, 2nM rfVa
FF/MI
; open inverse triangles, 5nM rfVa
FF/MI
; open 
diamonds, 5nM fXa in the absence of cofactor; stars, 5nM fXa in the presence of 
concentrated medium from plates of Cos 7 cells that were not transfected. All reactions 
were performed in triplicate and error bars are representative of standard deviation. 
Graphs were generated using Prisma 2.01 graphing software.  
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assembled into prothrombinase, however thrombin production was still accelerated over 
lipid-bound fXa in the absence of a cofactor molecule (open diamonds). Increasing the 
concentration of the rfVa
FF/MI
 to 5nM increased the ability of prothrombinase assembled 
with rfVa
FF/MI
 (open triangles) to generate thrombin demonstrating a rate similar to that 
of prothrombinase assembled in the presence of 1nM rfVa
MI
 (filled diamonds). Since all 
the recombinant molecules were assayed in concentrated medium the possibility that the 
observed increased catalyst by fXa was a result of an unknown factor present in the 
cultured medium had to be assayed. This possibility was assayed using an equal volume 
of concentrated cultured medium from plates of Cos 7 cells that were not transfected. The 
addition of the conditioned medium (stars) to a reaction mixture containing lipid-bound 
fXa displayed similar capabilities for thrombin generation as that of the reaction 
performed by lipid-bound fXa in the absence of fVa (open diamonds). 
 Since the rfVa
FF
, rfVa
MI
 and rfVa
FF/MI
 were generated to diminish fVa association 
with fXa, activity assays in the presence of an increased concentration of the recombinant 
cofactors were performed to determine if the impaired binding could be overcome by an 
increased cofactor concentration. Figure 4 shows the results of activity assays performed 
with 1nM rfVa
WT
, rfVa
FF
 and rfVa
MI
 in the presence of 5nM fXa. What we observe was 
that both the rfVa
FF
 (circles) and the rfVa
MI
 ability to accelerate thrombin generation by 
fXa increased in a fashion similar to that of 500pM rfVa
WT
 cofactor. This demonstrates 
that the weaken interaction between the recombinant mutants and fXa can be partially 
compensated for by increasing the concentration of the cofactor. Since the rfVa
FF/MI
 
combined mutations within the interactive site for fXa displays the greatest diminished 
activity in assays measuring thrombin generation, the  concentration  of  this  mutant  was 
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Figure 2.4 – Activity assays with increased concentrations of the recombinant fVa 
molecules. Initial rates of thrombin generation were determined at ambient 
temperature employing 5nM fXa in activity assays as described in the experimental 
procedure section. The various reactions are: filled squares, 1nM rfVa
WT
; filled circles, 
1nM rfVa
FF
; filed diamonds, 1nM rfVa
MI
; filled triangles, 10nM rfVa
FF/MI
. All 
reactions were performed in triplicate and error bars are representative of standard 
deviation. Graphs were generated using Prisma 2.01 graphing software.    
Figure 2.4 
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increased to 10nM (Diamonds) to determine if the fXa interaction could be restored. 
What is observed when 10nM rfVa
FF/MI
 is assembled into prothrombinase the ability to 
accelerate the generation of thrombin is restored to a rate similar of the prothrombinase 
assembled with 1nM rfVa
MI
. Since the ability of the rfVa
FF/MI
 to properly interact with 
fXa is compromised figure 4 also demonstrates the contribution of the light chain to the 
fVa/fXa interaction and the importance of the heavy chain of fVa for the proper 
interaction with fXa.  
 To visualize the activation pattern of prothrombin by prothrombinase assembled 
with the various recombinant mutants SDS PAGE was employed. Figure 5 compares the 
ability of prothrombinase assembled with the various recombinant molecules to activate 
prothrombin as compared to the control reactions catalyzed with prothrombinase 
assembled with plasma-derived fVa (panel B) and lipid-bound fXa in the absence of 
cofactor (panel A). The reaction catalyzed by lipid-bound fXa demonstrate the inability 
of timely prothrombin activation in the absence of cofactor, showing little consumption 
of prothrombin after 1 hour of incubation and initial cleavage occurring at Arg
271
 as 
evident by the formation of the prethrombin 2 intermediate. When 10nM plasma derived 
fVa is added into the reaction mixture all of the prothrombin is consumed within the first 
10 minutes of the reaction demonstrating the optimal rate of thrombin generation and a 
reversal of the cleavage pattern with an initial activating cleavage occurring at Arg
320
 as 
evident by the generation of fragment 1·2A. Panel C shows the reaction catalyzed by 
prothrombinase assembled with 10nM rfVa
WT
 and demonstrates a rate of thrombin 
production comparable to that of the prothrombinase assembled with plasma-derived fVa. 
Reactions   catalyzed  with   prothrombinase  assembled   with  10nM   rfVa
FF
,  rfVa
MI
  or 
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Figure 2.5 – SDS PAGE analysis of prothrombinase assembled with 
recombinant fVa mutants. To investigate the effects of the various rfVa mutants in 
the activation of prothrombin, prothrombinase was assembled under the following 
conditions: 0.5nM fXa, 10nM fVa species (when present), 10M DAPA, 20M 
PCPS and 1.4M prothrombin. Panel A shows the activation of prothrombin by 
lipid-bound fXa in the absence of fVa. Panel B shows the activation of prothrombin 
by prothrombinase assembled with plasma derived fVa. Panel C-F shows the 
activation of prothrombin assembled with the recombinant fVa molecules, rfVa
WT
, 
rfVa
FF
, rfVa
MI
 and rfVa
FF/MI
 respectively. Reaction mixtures were assembled in 
trizma buffered saline solutions in the presence of 5mM CaCl2 and aliquots were 
removed and prepared for SDS PAGE before and 20, 40, 60, 80, 100, 120, 140, 160, 
180, 200, 220, 240, 300, 360, 600, 1200, 1800 and 3600 seconds after the addition of 
fXa. The prothrombin derived fragments are labeled: II, prothrombin (residues 1-
579); F1·2A, fragment 1·2 A chain (residues 1-320); F1·2, fragment 1·2 (residues 1-
271); P2, prethrombin 2 (residues 271-579); B, B chain of thrombin (residues 321-
579) and F1, fragment 1 (residues 1-155). 
Figure 2.5 
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16.7 0.92 + 0.08 
fVa
FF/MI
 Assembled 
Prothrombinase 
2.3 6.7 + 0.03 
fVa
MI
 Assembled 
Prothrombinase 
3.14 4.9 + 0.4 
fVa
FF
 Assembled 
Prothrombinase 
  15.4 + 0.9 
fVa
WT
 Assembled 
Prothrombinase 
  0.0 + 0.09 Lipid-Bound fXa 
  moles consumed/moles fXa   
 
Fold Decrease 
 
Prothrombinase Consumption  
 
Enzyme 
Table 2.1 – Densitometry scanning of SDS PAGE in figure 5 of the rate of 
prothrombin consumption. Densitometry scanning of the acrylamide gels presented in 
figure 5 was performed to determine the rates of prothrombin consumption by 
prothrombinase assembled in the presence of the respective rfVa mutants. Rates are 
presented as moles of prothrombin consumed per mole of fXa and the fold decrease in the 
observed rates as compared to the reaction performed with prothrombinase assembled 
with rfVa
WT
 is presented. 
Table 2.1 
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rfVa
FF/MI
 are shown in panels D – F respectively. All of the recombinant mutants when 
assembled into a prothrombinase complex generate initial prothrombin activating 
cleavage at Arg
320
 as evident by generation of fragment 1·2A, though production of the 
meizothrombin intermediate is delayed for all of them. The prothrombinase catalyzed 
reactions assembled with rfVa
FF
 and rfVa
MI
 took over 30 minutes to consume all of the 
prothrombin present within the reaction, while prothrombinase assembled with rfVa
FF/MI 
was incapable of consuming all of the prothrombin present within the reaction mixture 
even after an hour incubation. 
 Densitometry scanning of SDS PAGE presented in figure 5 was performed to 
generate rates of prothrombin consumption presented in table 1. The optimal rate of 
prothrombin consumption under the condition employed throughout this series of 
experiments was 15.4 moles of prothrombin consumed per second per mole of fXa. The 
fold decrease of prothrombin consumption for the prothrombinase assembled with rfVa
FF
 
and rfVa
MI
 mutants were approximately the same being 3.2 and 2.3 respectively. While 
the fold decrease for the prothrombinase assembled with rfVa
FF/MI
 was much greater 
being 16.7 times slower in generating thrombin as compared to the prothrombinase 
assembled with the rfVa
WT
. 
 To assay the defective association between the recombinant fVa mutants with fXa 
in a more quantitative fashion the recombinant proteins were titrated against a limiting 
concentration of fXa to determine the apparent Kd values for the association of the fVa 
mutants with fXa. Figure 6 shows the results of this kinetic study using an activity based 
assay monitored through the cleavage of the chromogenic substrate S-2338, specific for 
thrombin. Prizma graphing software was used to generate the graph presented in figure 6  
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Figure 2.6 – Titration of rfVa molecules. To determine the apparent kd values for the 
recombinant rfVa molecules for fXa, fVa titrations were performed. Increasing 
concentrations of the respective rfVa molecules were assembled into prothrombinase 
in the presence of 15pM fXa, 10M DAPA, 20M PCPS and 1.4M prothrombin. 
Initial velocity of thrombin generation was assayed through the cleavage of the 
chromogenic substrate S-2238 and quantified by comparison to a thrombin standard. 
The empirically derived kd values are presented in table 2.  
Figure 2.6 
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10.9 + 2.4 fVa
FF/MI 
1.8 + 0.7 fVa
MI 
0.7 + 0.3 fVa
FF 
0.18 + 0.02 fVa
WT 
nM   
Kd
App 
fVa Species 
Table 2.2 – Apparent kd values for the rfVa molecules for fXa. The empirically 
derived kd values for the association of the various rfVa molecules with fXa. 
Values were determined by using Prisma 2.01 Graphing software to analyze the 
data presented in figure 6. 
Table 2.2 
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as well as the apparent Kd values that are presented in table 2. Comparison of the 
apparent Kd values for the rfVa
WT
 and the plasma-derived fVa demonstrate similar 
values for the interaction between these two molecules with fXa and is consistent with 
Kd values presented throughout the literature. The rfVa
FF
 and rfVa
MI
 displayed impaired 
association with fXa as demonstrated by the 4-fold and 10-fold increase in the apparent 
Kd values respectively. When the two sets of mutations within the A2 domain of fVa are 
combined within the rfVa
FF/MI
 mutant the increase in the apparent Kd value becomes 60-
fold showing a greatly hampered interaction between the rfVa
FF/MI
 mutant and fXa.  
 The determination of the apparent Kd values for the recombinant mutants enabled 
us to study the effects of the induced mutations to the overall function of the 
prothrombinase complex. The degree of saturation of fXa in the presence of a known 
concentration of the respective recombinant fV molecule was determined using the 
apparent Kd value. Equation 1 allows us to predict the percentage of fXa associated with 
the respective recombinant fVa molecules depending on the concentration of fVa used in 
the reaction thus allowing us to match the concentration of the prothrombinase complex 
(17). Matching the concentration of the prothrombinase complex, fXa associated with the 
respective recombinant fVa mutants, allowed us to measure the catalytic efficiencies of 
the different prothrombinase molecules. Figure 7 shows the results of matching 
concentrations of prothrombinase assembled with the various recombinant fVa molecules 
titrated with prothrombin as a means of measuring the apparent Kcat and Km values for the 
different prothrombinase molecules. The prothrombinase assembled with rfVa
WT
 
displayed Km and Kcat values comparable to that of the prothrombinase assembled with 
plasma derived fVa demonstrating that there was no functional defect with the wild type 
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Figure 2.7 – Determination of apparent Km and Kcat values. Prothrombinase 
assembled with saturating concentrations of the respective rfVa molecules as 
determined by the fVa titrations performed in figure 6 were performed to determine 
the respective Km and Kcat values for each of the recombinant mutations. Reactions 
mixtures composed of 0.5nM fXa, 20M PCPS, 10M DAPA and 5nM rfVaWT (filled 
squares), 15nM rfVa
WT
 (filled circles), 5nM plasma derived fVa (filled triangles), 5nM 
rfVa
FF
 (open diamonds), 5nM rfVa
MI
 (opened circles), and 30nM rfVa
FF/MI
 (filled 
inverse triangles) were initiated with increasing concentrations of prothrombin. Initial 
velocities were measured and quantified against a thrombin standard to determine the 
thrombin (nM) produced per minute for the respective prothrombinase molecules. 
Figure 2.7 
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Table 2.3 – Empirically derived kinetic values from prothrombin titrations 
presented in figure 7. The apparent Vmax, Km and Kcat values as determined using 
Prisma 2.01 Graphing software to analyze the prothrombin titrations presented in figure 
7 are shown for all of the prothrombin titrations performed. 
Table  2.3 
4.5 X 10 7 406 + 14 0.15 + 0.02 2.03 + 0.07 
2.4 X 10 8 2040 + 48 0.14 + 0.01 10.2 + 0.24 
3.0 X 10 8 1806 + 40 0.1 + 0.01 9.03 + 0.2 
2.1 X 10 8 1970 + 80 0.16 + 0.02 9.85 + 0.4 
2.7 X 10 8 1944 + 120 0.12 + 0.03 9.72 + 0.6 
    S
-1
 · M
-1
  Min
-1 M nMIIa/Min 
       Kcat/Km  Kcat Km VMaxApp 
fVa
FF/MI 
fVa
MI 
fVa
FF 
fVa
WT 
fVaPlasma 
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protein. These values were also consistent with the kinetic values well established 
throughout the literature. Both the rfVa
FF
 and the rfVa
MI 
demonstrated similar Kcat and 
Km values when the concentration of the cofactor molecules were increased to produce 
similar concentration of fXa associated with the respective mutant cofactor. However 
prothrombinase assembled with saturating concentrations of the rfVa
FF/MI 
molecule failed 
to recover the catalytic efficiency displayed by the other molecules used throughout this 
study. This deficiency is the result of the decreased Kcat displayed by prothrombinase 
assembled with the rfVa
FF/MI
 and can be attributed to the weakened interaction of the 
rfVa
FF/MI
 molecule with fXa. Table 3 shows the kinetic values obtained from figure 7 and 
demonstrate that none of the recombinant fVa molecules, when assembled into 
prothrombinase, affect the Km of the enzyme as evident by the small variance in the 
apparent Km values obtained. However the effect of the Kcat of the enzyme due to the 
weakened fVa/fXa interaction caused by the mutations within the proposed binding site 
varied greatly, suggesting that the proper interaction of the A2 domain of fVa with fXa is 
a prerequisite for optimal catalytic efficiency of prothrombinase. 
 The kinetic study provided within figures 6-7 and tables 1-2 enable the calculation 
of the thermodynamic cycle presented in figure 8. As figure 8 demonstrates, the 
interaction between the two mutated regions demonstrated an additive effect suggesting 
that the two mutated regions (i.e., rfVa
FF
 and rfVa
MI
) have a cooperative effect between 
each other when the heavy chain of fVa associates with fXa. The overall exchange in free 
energy between the two altered sites as determined by equation 4 is 1.21 kcal/mol 
demonstrating that the two sites interact with each other when the associating with fXa. 
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Factor  Va wt Factor  Va FF 
Factor  Va MI Factor  Va 
 
FF /MI 
+0.92 kcal/mol 
 G 
int = +1.21 kcal/mol 
+1.1kcal/mol 
- 0.21  kcal/mol 
+1.0 kcal/mol 
- 0.08 kcal/mol 
Figure 2.8 
Figure 2.8 – Thermodynamic cycle for prothrombinase assembled with the 
various rfVa molecules. The GINT is the free energy of the interaction between the 
323
EY
324
 and 
330
EV
331
 residues and was calculated according to equation 4 as presented 
in the materials and methods section.  
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To assay the effects of the decreased fVa/fXa interaction on the individual 
prothrombin activating cleavages independently of each other, SDS PAGE was employed 
on prothrombinase catalyzed activation of the recombinant prothrombin mutants rP2-II 
(R
155
  A, R284  A and R320  A) and rMZ-II (R155  A, R271  A and R284  A) 
which are only capable of being cleaved at Arg
271
 and Arg
320
 respectively. Figure 9 
shows the results from reactions using the different prothrombin mutants as substrate for 
the enzymes; lipid-bound fXa (panel A), prothrombinase assembled with plasma-derived 
fVa (panel B), prothrombinase assembled with rfVa
WT
 (panel C), prothrombinase 
assembled with rfVa
FF
 (panel D), prothrombinase assembled with rfVa
MI
 (panel E) and 
prothrombinase assembled with rfVa
FF/MI
 (panel F). Prothrombinase assembled with 
rfVa
WT
 (panel C) displayed comparable catalysis of both of the prothrombin mutants 
when compared to prothrombinase assembled with plasma-derived fVa. Prothrombinase 
assembled with the rfVa
FF
 (panel D) and rfVa
MI
 (panel E) displayed slower consumption 
of both rP2-II and rMZ-II approximately 8 and 5 fold respectively as shown in table 4. 
While the prothrombinase assembled with rfVa
FF/MI
 showed the greatest deficiency when 
using rP2-II or rMZ-II as substrates. Densitometry scanning of SDS PAGE presented in 
figure 9 was performed and the results are presented in table 4 establishing that the fold 
decrease in the ability of prothrombinase assembled with rfVa
FF
 or rfVa
MI
 respectively to 
cleave both substrates rP2-II and rMZ-II are similar. Interestingly the reactions performed 
in the presence of prothrombinase assembled with rfVa
FF/MI
 showed a dissimilar fold 
decrease in its ability to cleave rP2-II (an 8.8-fold decrease) or rMZ-II (a 17.6-fold 
decrease) suggesting that the interaction of the A2 domain with fXa is more important for 
the catalyzed cleavage at Arg
320
.                                  
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Figure 2.9 – Prothrombinase assembled with the various rfVa mutants were assayed 
for their ability to cleave the recombinant prothrombin mutants rP2-II and rMZ-II 
which are only capable of being cleaved at one of the two activating sites as described 
in the experimental procedures section. Reactions mixtures were composed of by 
0.5nM fXa, 10nM fVa species (when present), 10M DAPA, 20M PCPS and 1.4M 
of the respective recombinant prothrombin molecules in a HEPES buffered saline 
solution. In all cases lanes 1-9 shows reactions using the rMZ-II mutant as the 
substrate, while lanes 10-18 are reactions which employed the rP2-II mutant as the 
substrate. Panel A shows the results from a fXa catalyzed reactions, panel B shows the 
results from a reactions catalyzed by prothrombinase assembled with plasma derived 
fVa, panel C shows the reactions catalyzed by prothrombinase assembled with 
rfVaWT, Panel D shows the reactions catalyzed by prothrombinase assembled with 
rfVa
FF
, panel E shows the reactions catalyzed by prothrombinase assembled with 
rfVa
MI
 and panel E shows the reactions catalyzed by prothrombinase assembled with 
rfVa
FF/MI
. For all of the reactions lanes 1-9 and 10-18 are aliquots removed from 
reactions mixtures and quenched at the following time points after the addition of fXa: 
0 min (before the addition of fXa), 0.5 min, 1 min, 2.5 min, 4 min, 6 min, 10 min, 20 
min and 30 min. The prothrombin derived fragments are the same as explained in the 
figure legend to figure 5.   
Figure 2.9 
A B C 
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       Enzyme  
rMZ-II 
(Cleavage 
at Arg320) 
(moles consumed • 
sec-1 • mole 
factor Xa-1) 
 
 
Fold 
decrease 
rP2-II 
(Cleavage 
at Arg271) 
(moles consumed 
• sec-1 • mole 
factor Xa-1) 
 
 
Fold 
decrease 
Factor Xa alone 0.07 ± 0.11 -- 0.05 ± 0.08 -- 
Prothrombinase 
with wild type 
24.6 ± 2.8 -- 2.72 ± 0.23 -- 
Prothrombinase 
with factor Va
FF
 
2.8 ± 0.2 8.8 0.33 ± 0.04 8.2 
Prothrombinase 
with factor Va
MI
 
4.6 ± 0.5 5.3 0.52 ± 0.04 5.2 
Prothrombinase 
with factor Va
FF/MI
 
1.4 ± 0.1 17.6 0.31 ± 0.06 8.8 
 
 
 
 
 
 
 
 
 
 Table 2.4 
Table 2.4 – Densitometry scanning of the consumption of recombinant 
prothrombin molecules. The SDS PAGE presented within figure 9 were subjected to 
densitometry scanning to determine the rate of prothrombin consumption by 
prothrombinase assembled in the presence of the various fVa molecules. The fold 
decrease of the rate of consumption of the recombinant prothrombin molecules were 
measured by comparison to the rate of prothrombin consumption by prothrombinase 
assembled with rfVa
WT
.   
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2.5 DISCUSSION   
Previous studies demonstrated that activated protein C (APC) degrades fVa in a 
fashion resulting in the removal of the A2 domain from fVa and a loss of the fVa/fXa 
interaction (21,22). Synthetic peptides designed to study this region have shown that 
N42R (a synthetic peptide designed with the corresponding sequence from residues 307-
348 of the heavy chain of fVa) is capable of mimicking the APC degradation of fVa loss 
of function by strongly inhibiting prothrombinase activity (23). Further peptide studies 
have shown that residues 323-324 and 330-331 in fVa are involved in binding fXa and 
are required for the coordinated cleavage of prothrombin by fXa (11-13). All of the above 
studies imply the involvement of the A2 domain of fVa in the recognition fXa. The 
present study explores these residues involvement in both the assembly and function of 
prothrombinase through the generation of recombinant molecules with mutations in these 
residues.  
The elevated Kd values for prothrombinase assembled with the rfVa
FF
, rfVa
MI
 and 
rfVa
FF/MI
 molecules illustrate a decreased interaction between the respective molecules 
with fXa and demonstrate the necessity of these residues for the proper interaction of fVa 
with fXa. All of the recombinant molecules when assembled into prothrombinase 
displayed similar Km values indicating that the induced mutations had no detrimental 
effect on the ability of the different prothrombinase molecules in recognizing the 
substrate prothrombin and showing the selective nature of the damaging effects of the 
mutated sites. Both the rfVa
FF
 and rfVa
MI
 mutants were able to fully recover their 
catalytic efficiency when their respective concentrations were increased to compensate 
for their weakened interaction with fXa. This was not the case when the two mutated 
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regions were joined together into a single construct, the catalytic efficiency of 
prothrombinase assembled with rfVa
FF/MI
 was not restored when fXa was fully saturated 
with the rfVa
FF/MI
. The loss of multiple binding sites for fXa could have caused a 
damaging in fVa’s ability to function as a cofactor molecule for fXa, one that could not 
be compensated for by simply increasing the concentration of rfVa
FF/MI
, though the 
possibility that the induced mutations altered the conformation of fV in a manner that was 
detrimental to function of prothrombinase cannot be excluded as an opposing cause of the 
result presented within this study. 
Presently this recombinant study demonstrates that decreasing the affinity of fVa for 
fXa causes a decrease in the ability of prothrombinase to efficiently generate thrombin, 
suggesting that the interaction of fVa with fXa increases the catalytic capability of fXa. 
This study shows that residues 323, 324, 330 and 331 of the A2 domain of fVa are 
important for the association between fVa and fXa and that the loss of any of these sites 
will result in a weakened interaction between fVa and fXa that can be compensated for 
by increasing the concentration of the cofactor molecule, but a loss of all of these 
residues result in a cofactor molecule that is incapable of interacting properly with fXa 
and consequently incapable of properly functioning as a cofactor.  
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CHAPTER III 
A CONTROL SWITCH FOR PROTHROMBINASE 
3.1 ABSTRACT 
Previous studies have demonstrated that residues 695-698 of the A2 domain of the heavy 
chain of fVa are involved in recognition of prothrombin by prothrombinase and that a 
synthetic peptide representative of this region strongly inhibits prothrombinase by 
substrate depletion. We have shown that a pentapeptide representative of this region 
(DYDYQ (D5Q)) strongly inhibits thrombin generation by prothrombinase by 
specifically inhibiting the initial prothrombinase catalyzed cleavage of prothrombin at 
R
320
. In contrast, the interaction of D5Q with prothrombin accelerates the rate of initial 
cleavage at R
271
 of prothrombin in reactions catalyzed by lipid-bound fXa, however 
thrombin production is inhibited due to a slower rate of the subsequent cleavage at R
320
 
of the prethrombin2/fragment 1·2 intermediate. Recombinant prothrombin molecules 
only capable of being cleaved at one of the activation sites were used to confirm results 
obtained with plasma-derived prothrombin; rMZ-II (R
155
  A, R271  A and R284  A) 
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and rP2-II (R
155
  A, R284  A and R320  A). Comparison of prothrombinase 
inhibition by D5Q with the hirudin derived peptides demonstrated dissimilar inhibitory 
patterns. While the hirudin peptides strongly inhibited the prothrombinase catalyzed 
activation of prethrombin 1 in the absence and the presence of fragment 1, D5Q 
demonstrated little inhibition in these reactions. In contrast the prothrombinase catalyzed 
activation of the prethrombin 2/fragment 1·2 intermediate was strongly inhibited in the 
presence of D5Q, while the hirudin peptide showed little inhibition in this reaction. In 
conclusion, D5Q strongly inhibits thrombin generation by both prothrombinase and lipid-
bound fXa in a manner independent from the hirudin peptides.          
3.2 INTRODUCTION 
The maintenance of blood vessel integrity is dependent on the timely generation 
of thrombin in response to vascular injury. Thrombin is generated through two sequential 
activating cleavages occurring at Arg
271
 and Arg
320
 catalyzed by membrane-bound 
activated factor X (fXa). Though membrane-bound fXa catalyzes both of the activating 
cleavages on the zymogen prothrombin, membrane-bound fXa is inefficient in this 
process in the absence of activated factor V (fVa). The association of fXa with fVa on a 
membrane surface in the presence of divalent metal ions results in the formation of the 
prothrombinase complex (1). The formation of the prothrombinase complex results in a 
reversal of the activating cleavages of prothrombin accompanied by a 300,000 fold 
increase in the rate of thrombin formation (2). 
 Membrane-bound fXa activates prothrombin through initial activating cleavage 
occurring at Arg
271
 resulting in the enzymatic inactive intermediate prethrombin 2 
(residues 272-579) and fragment 1·2 (residues 1-271). Subsequent cleavage of 
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prethrombin 2 at Arg
320
 produces the active enzyme thrombin. The incorporation of fVa 
into the prothrombinase complex directs catalysis by fXa in a manner resulting in a 
reversal of the order of the activating prothrombin cleavages (3). The prothrombinase 
complex initial cleavage of prothrombin occurs at Arg
320
 generating the meizothrombin 
intermediate (4). Meizothrombin is an enzymatic intermediate that is quickly consumed 
by prothrombinase by cleavage at Arg
271
 to generate thrombin. Figure 1 shows the two 
pathways to thrombin generation as catalyzed by membrane-bound fXa and the 
prothrombinase complex. The molecular details on fVa’s involvement in prothrombinase 
are not well understood. 
 The zymogen factor V (fV) is composed of three homologous A domains, a B 
domain and two homologous C domains that are arranged in an A1-A2-B-A3-C1-C2 
fashion (5). The zymogen fV is composed of 2196 amino acids and has a relative 
molecular weight of 330,000. Proteolytic activation of fV occurs through three sequential 
thrombin catalyzed cleavages occurring after residues Arg
709
, Arg
1018
  and Arg
1545
 
resulting in an amino-terminally derived heavy chain composed of residues 1-709 
associated through Ca
2+
 to the carboxyl-terminally derived light chain composed of 
residues 1546-2196 (6,7). The activated cofactor, fVa, is involved in recognition of all of 
the components of prothrombinase. It is well established that both the heavy and light 
chains of fVa interact with fXa and that the light chain of fVa is involved in interacting 
with activated membrane surfaces (8-10). It has also been demonstrated on several 
occasions that the carboxyl-terminal region of the heavy chain is involved in substrate 
recognition by directly interacting with prothrombin (11-14). 
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The carboxyl-terminal region of the heavy chain of fVa has a highly acidic region 
that shares homology with hirudin, a known anticoagulant molecule that inhibits 
prothrombin activation by directly interacting with prothrombin (15). We have recently 
shown that a synthetic pentapeptide from this region with the sequence DYDYQ 
(representative of residues 695-699) strongly inhibits thrombin generation by 
prothrombinase (16). This peptide has also been shown to directly inhibit thrombin 
mediated activation of fV (17). A recent recombinant study deleted the carboxyl terminal 
region of the heavy chain of fV and showed the cofactor had decreased specific activity 
in clotting assays (~80%), while activity based assays suggested an increased rate of 
thrombin production (~120%) (18).  
3.3 EXPERIMENTAL PROCEDURES 
 Materials, reagents and proteins – L--phosphatidylserine (PS) and L--
phosphatidylcholine (PC) were purchased from Avanti Polar Lipids (Alabaster, AL) and 
prepared as previously described (19) followed by quantification by a phosphorus assay 
as previously described (20). The chromogenic substrate Spectrozyme-TH, normal 
reference plasma and fII deficient plasma were purchased from America Diagnostica, Inc 
(Greenwich, CT). Human -thrombin, prothrombin, prethrombin 1, prethrombin 2, 
fragment 1·2, fragment 1, fragment 2, and the fluorescent thrombin inhibitor 
dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (Dapa), were purchased from 
Hematologic Technologies, Inc. (Essex Junction, VT). The monoclonal antibody hFV1 
coupled to Sepharose, and the two monoclonal antibodies against factor V (against the 
heavy and the light chains respectively, HFVHC#17 and HFVLC#9) were provided by 
Dr. Kenneth G. Mann (Department of Biochemistry, University of Vermont, Burlington, 
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VT). Human fXa was purchased from Enzyme Research Laboratories (South Bend, IN). 
Diisopropyl fluorophosphates (DFP), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(Hepes), Trizma base, Coomassie Blue R-250, Hirudin 54-65 (sulfated hirudin, Hir
54-65
 
(SO3
-
)), hirudin 54-65 (Hir
54-65
, non-sulfated hirudin) and factor V-deficient plasma were 
purchased from Sigma. Polyethylene glycol (Mr 8000) was purchased from J. T. Baker 
(Danvers MA). The chemiluminescent reagent ECL
+
 and heparin-Sepharose were from 
Amersham Biosciences. The thromboplastin reagent (recomboplastin) used in the clotting 
assays was purchased from Beckman (Fullerton, CA). The pentapeptide DYDYQ (D5Q) 
and its sulfated version (D5Q1,2) were custom synthesized by New England Peptide Inc. 
(Gardner, MA) and by American Peptide Company (Sunnyvale, CA). Human fV and fVa 
were purified and concentrated using methodologies previously described employing the 
monoclonal antibody hFV#1 coupled to sepharose and heparin-sepharose (21-23). The 
recombinant prothrombin molecules, rP2-II and rMZ-II, were prepared and purified as 
previously described (24,25).   
Procedures for Working with Synthetic Peptides – All peptides were custom made 
by New England Peptide and stored in a desiccator at -20ºC for future use. Samples 
weighing between 3 – 5mg of peptides were diluted in 1ml of water and thoroughly 
mixed followed by centrifugation at 14,000RPM for 5 minutes to remove any particles 
not in solution. Aliquots of every peptide preparation were frozen for sequence analysis 
to confirm the concentration and composition of the peptides, and all peptides solutions 
were used within a week or stored at -20°C for future use. The concentration of the 
peptides was calculated based on the weight (mg) of peptide divided by the volume of 
water (ml) dissolved corrected for the percent peptide concentration provided by New 
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England Peptide. All calculated concentrations were confirmed through amino-terminal 
sequence analysis of every peptide solution.     
Measuring D5Q Inhibition of Prothrombin Activation – Activity assays 
measuring the inhibitory potential of D5Q were monitored through cleavage of a 
chromogenic substrate specific for thrombin. Incubation of prothrombin with increasing 
concentrations of D5Q or an equivalent volume of buffer was performed for 10 minutes 
before addition into reaction mixtures. Since D5Q inhibition has been shown to act on the 
substrate, reactions were performed in the presence and absence of fVa to assay the 
effects the interaction of prothrombin with the peptide has on prothrombinase and fXa 
catalyzed reactions independently. In both cases reaction mixtures contained 20M PCPS 
and 10M DAPA in a HEPES buffer containing 5mM Ca2+. Results are presented as 
percent control with respect to the control reactions performed in the absence of D5Q. All 
reactions were performed in triplicate and the graphing program Prisma 2.01 was used for 
interpreting data and generating graphs of percent inhibition against D5Q concentration.      
SDS Page Analysis of D5Q Inhibition on Prothrombin Activation. – The effects 
D5Q inhibition has on prothrombin activation was visualized and monitored through SDS 
PAGE of both prothrombinase and fXa catalyzed reactions. Titration of prothrombinase 
and fXa catalyzed reactions with increasing concentrations of D5Q demonstrated the 
concentration dependence of D5Q inhibition and indicated which pathway to 
prothrombin activation was used or inhibited. Measurements of prothrombin 
consumption were performed through densitometry scanning using U-SCAN-IT software. 
In all cases prothrombin was incubated with increasing concentrations of D5Q for 10 
minutes at ambient temperature before addition into reaction mixtures containing 20M 
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PCPS, 10M DAPA and 10nM fVa when present. Aliquots of the reaction mixture 
before the addition of fXa were removed and placed in two fold volume of 0.2M acetic 
acid for a sample before the reaction was initiated. Reactions were initiated by the 
addition of fXa and additional time points were removed along the course of the reaction 
and placed into 0.2M acetic acid to stop the reaction. A centrivap was used to concentrate 
all samples followed by reconstituted in 0.1M Trizma buffer, 1% BME and 1% SDS at 
pH 6.8. SDS PAGE was stained with coomassie blue and densitometry scanning was 
performed to measure the rates of prothrombin consumption throughout both series of 
titrations. Comparison of the rates obtained from inhibited reactions to control reactions 
performed in the absence of D5Q were performed.  
D5Q Inhibition With Respect to Individual Prothrombin Cleavages –The effects 
of D5Q inhibition on the individual prothrombin activating cleavages were determined 
independently of each other using the recombinant prothrombin molecules rMZ-II and 
rP2-II which are only capable of being cleaved at R
320
 and R
271
 respectively. SDS PAGE 
monitored both prothrombinase and fXa catalyzed reactions titrated with D5Q using 
either rMZ-II or rP2-II as substrate for the reactions. This allowed us to measure the 
inhibitory effect of D5Q on both prothrombin activating cleavages independently. 
Incubation of the respective prothrombin mutants with D5Q was performed at ambient 
temperature for 10 minutes before addition into the reaction mixtures. Aliquots of 5g 
were removed from reaction mixture before and at specific time intervals after the 
addition of fXa and placed in two fold volume of 0.2M acetic acid followed by 
concentration in a centrivap for preparation of SDS PAGE. Stained gels were subjected to 
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densitometry scanning to measure the rate of rMZ-II or rP2-II consumption and 
compared to the rates of the uninhibited control reactions performed at the same time.  
Plasma-Derived Prothrombin Fragments - Since the activation of prothrombin 
consists of more than one activating cleavage, the physiological substrates of 
prothrombinase include all of the normally occurring prothrombin derivatives. The 
prothrombin fragments used throughout this series of experiments were purchased from 
HTI and consist of prothrombin (residues 1-579), prethrombin 1 (residues 156-579), 
prethrombin 2 (residues 272-579), fragment 1·2 (residues 1-271), fragment 1 (residues 1-
155) and fragment 2 (residues 156-271). All proteins were dialyzed in trizma buffered 
saline solution composed of 20mM trizma at pH 7.40 containing 5mM CaCl2. Their 
concentrations were determined using the extinction coefficients (1%280nm) and molecular 
weights as follows; prothrombin 13.8 and 72,000, prethrombin 1 17.8 and 50,500, 
prethrombin 2 17.3 and 37,000, fragment 1·2 11.2 and 34,500 and thrombin 18.3 and 
36,700. Protein aliquots were frozen after dialysis for future use. Reactions using the 
substrate prethrombin 1 were performed in the presence and the absence of fragment 1 
and reactions using the substrate prethrombin 2 were performed in the presence and 
absence of fragment 1, fragment 2 and fragment 1·2. The substrate concentration for all 
reactions was at least twice that of their reported Km to ensure maximum velocity of the 
uninhibited enzyme and specific reaction conditions are given in the figure legends.  
Activity Assays for Determining Thrombin Production – Measurements of the rate 
of activation of prothrombin and prothrombin derived fragments were performed in a 
discontinuous assay monitored through cleavage of a chromogenic substrate specific for 
thrombin (Spectrozyme TH, America Diagnostica). Reactions mixtures were prepared in 
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a HEPES buffered saline (20mM HEPES) solution containing 5mM CaCl2 and initiated 
by the addition of fXa. Several time points from the first two minutes of the reaction were 
removed and immediately quenched in a HEPES buffered saline solution containing 
EDTA to stop the reaction. All reactions were compared to a thrombin standard for 
quantitative purposes. Initial velocities were determined using Prism graphing software to 
generate graphs of OD vs. time (seconds) followed by comparison of the slopes of the 
reactions to a thrombin standard for quantification of reactions. Results using peptides 
were always compared to reactions performed without peptide and percent inhibition was 
determined by comparison of inhibited reactions to the control reactions.   
SDS PAGE of Reactions – In all cases the substrate used in any reaction was 
incubated in the presence of D5Q for ten minutes at ambient temperature before addition 
into reaction mixtures. Reactions catalyzed by prothrombinase or fXa alone were initiated 
by the addition of fXa. Aliquots of 4-6g of protein from the reaction mixture were 
removed at various time points determined empirically dependent on the substrate used 
(i.e. prothrombin, prethrombin 1 or prethrombin 2) and placed in a two-fold volume of 
0.2 M acetic acid to stop the reaction. Samples were then concentrated using a centrivap 
attached to a cold trap and suspended in a loading buffer containing 1% SDS and 1% 
BME followed by preparation for SDS PAGE. Control reactions performed in the 
absence of peptides were performed simultaneously with reactions performed in the 
presence of peptide as a means of ensuring any differences in reaction rates or pathways 
were due to the presence of the peptides being used. Differences in cleavage patterns 
were determined according to molecular weights of products and confirmed through 
amino terminal sequencing. Differences in the rates of cleavage were determined by 
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densitometry scanning of SDS-PAGE followed by comparison to control reactions 
performed in the absence of peptide.   
3.4 RESULTS 
 Previous studies demonstrated that the pentapeptide D5Q was a competitive 
inhibitor of prothrombinase with respect to prothrombin and that inhibition occurred by 
substrate depletion. The current study was performed to ascertain the effect D5Q has on 
the pathway to thrombin generation by prothrombinase. Figure 2 shows the titration of a 
prothrombinase catalyzed reaction with D5Q. The titration demonstrates that inhibition is 
concentration dependent and shows 50% inhibition occurs at 7.5M D5Q under the 
conditions employed. As the concentration of D5Q was increased complete inhibition 
never occurred though approached 100% inhibition at 15M D5Q.   
 To directly assay the effect of the peptide on the pathway to thrombin generation 
in a prothrombinase catalyzed reaction SDS PAGE was performed. This allowed the 
determination of the intermediates involved. The results presented in figure 3 show the 
effect D5Q has on the pathway to prothrombin activation. Panel A shows a control 
reaction performed in the absence of peptide and demonstrates the normal pathway to 
thrombin production by prothrombinase. Prothrombin is rapidly consumed with initial 
activating cleavage occurring at Arg
320
 producing meizothrombin, as evident by the 
appearance of fragment 1·2A. The subsequent cleavage at Arg
271
 quickly consumes the 
transient meizothrombin intermediate and generates thrombin and fragment 1·2. All of 
the prothrombin present within the reaction mixture is consumed within ten minutes 
resulting in complete conversion of the prothrombin to thrombin. Panel B shows a 
prothrombinase  catalyzed  activation  of  prothrombin   in  the  presence  of  a  saturating  
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Figure 3.1 – The activation of prothrombin. Pathway 1 - Membrane-bound fXa 
catalyzes initial cleavage at Arg
271
 producing the inactive intermediate prethrombin 2 
and fragment 1·2. Prethrombin 2 is then sequentially cleaved at Arg
320
 to produce 
thrombin and fragment 1·2. Pathway 2 – In the presence of fully assembled 
prothrombinase complex the rate of thrombin generation is greatly enhanced and the 
order of the activating cleavages on prothrombin are reversed. Prothrombinase initially 
cleaves prothrombin at Arg
320
 generating the active enzymatic intermediate, 
meizothrombin. Meizothrombin is then cleaved at Arg
271
 to produce thrombin and 
fragment 1·2. 
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Figure 3.2 – DYDYQ titration of prothrombinase catalyzed activation of 
prothrombin. Reaction mixtures composed of 5nM fVa, 0.5nM fXa, 50M DAPA 
and 10M PCPS assembled in a HEPES buffered saline solution containing 5mM 
CaCl2 were started by the addition 1.4M prothrombin that was incubated with 
increasing concentration of DYDYQ for ten minutes. All reactions were performed in 
triplicate and compared to control reactions that were performed in the absence of 
DYDYQ. Error bars are representative of standard deviance and Prisma Graphing 
software was used in generating the graph. 
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Figure 3.3 – SDS PAGE analysis of prothrombin activation. Reactions performed 
in the absence and the presence of DYDYQ were subjected to SDS PAGE analysis to 
determine the effect DYDYQ had on the pathway to thrombin generation. Panel A 
shows a prothrombinase catalyzed reaction demonstrating the optimal rate of the 
reaction with initial cleavage occurring at Arg
320
 as evident by the presence of F1·2A. 
Panel B shows a prothrombinase catalyzed reaction performed in the presence of 
20M DYDYQ and demonstrates initial cleavage occurring at Arg271 as evident by the 
presence of prethrombin 2. Aliquots from both reaction mixtures were removed at 0, 
20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 300, 360, 600, 1200, 1800 and 
3600 seconds after the addition of fXa. The prothrombin derived fragments are 
labeled: II, prothrombin (residues 1-579); F1·2A, fragment 1·2 A chain (residues 1-
320); F1·2, fragment 1·2 (residues 1-271); P2, prethrombin 2 (residues 271-579); B, B 
chain of thrombin (residues 320-579).    
CONTROL 20 M DYDYQ 
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Figure 3.3 
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concentration of D5Q (20M). In the presence of 20M D5Q prothrombin consumption 
by prothrombinase is greatly delayed with the initial activating cleavage occurring at 
Arg
271
 as evident by the occurrence of prethrombin 2 and fragment 1·2. The subsequent 
cleavage occurring at Arg
320
 produces thrombin at a greatly delayed rate. Prothrombin 
was still present within the reaction mixture after an hour of incubation. 
 To determine the concentration dependence of the peptide on the switch in 
pathways and the concentration at which meizothrombin formation is completely 
inhibited a titration of D5Q on a prothrombinase catalyzed reaction was monitored 
through SDS PAGE. Figure 4 shows the effects of increasing concentrations of D5Q on 
prothrombinase activation of prothrombin. Panels A – D demonstrate the disappearance 
of fragment 1·2A, representative of meizothrombin, corresponding to an increased 
production of prethrombin 2 as seen in panels C – F. As the concentration of D5Q is 
increased from 2M to 4.2M the preferred pathway to thrombin formation by 
prothrombinase switches from the meizothrombin intermediate to the prethrombin 2 
intermediate, because the initial activating cleavage of prothrombin by prothrombinase 
switches from Arg
320
 to Arg
271
 and consequently the rate at which prothrombin is 
consumed is greatly inhibited. Densitometry scanning of SDS PAGE presented in figure 
4 show the rate decrease of prothrombin consumption in the presence of varied 
concentrations of D5Q. A 41-fold decrease in the rate of prothrombin consumption is 
observed as the concentration of the peptide is raised to 20M.  
 To assay the peptide’s effect of the peptide on both prothrombin activating 
cleavages independently of each other, two recombinant prothrombin mutants were 
employed which were only capable of one activating cleavage. The prothrombin mutants  
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Figure 3.4 – SDS PAGE analysis of DYDYQ titration of prothrombinase 
catalyzed reaction. Plasma derived prothrombin was incubated with increasing 
concentrations of DYDYQ as indicated in the figure. The time points and the 
prothrombin derived fragments are the same as indicated in figure legend 3. The 
concentrations of DYDYQ used throughout this experiment were: Panel A, 
prothrombinase in the presence of 0M DYDYQ; panel B, prothrombinase in the 
presence of 0.2M DYDYQ; panel C, prothrombinase in the presence of 2M 
DYDYQ; panel D, prothrombinase in the presence of 4.2M DYDYQ; panel E, 
prothrombinase in the presence of 8.5M DYDYQ; panel F, prothrombinase in the 
presence of 16.5M DYDYQ. 
Figure 3.4 
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Peptide Concentration 
Plasma-derived 
Prothrombin Fold Decrease 
M 
moles consumed · s-
1         · mole fXa-1  
0 8.2 + 0.6  
0.2 5.4 + 0.6 1.5 
4.2 3.2 + 0.4 2.6 
8 0.87 + 0.3 9.4 
8.5 0.5 + 0.2 16.4 
16.5 0.4 + 0.2 20.5 
20 0.2 + 0.2 41 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1 
Table 3.1 – Scanning densitometry. The rates of prothrombin consumption in the 
presence of increased DYDYQ concentrations were generated through densitometry of 
the gels presented in figures 3 and 4. The fold decrease in the rate of prothrombin 
consumption was generated as a ratio of the prothrombinase catalyzed reaction 
performed in the absence of DYDYQ to the prothrombinase catalyzed reaction in the 
presence of DYDYQ. 
 72 
rMZ-II (R
155
  A, R271  A and R284  A) and rP2-II (R155  A, R284  A and R320  
A) were used in prothrombinase catalyzed reactions performed in the presence and 
absence of D5Q to assay the peptide’s effect on the individual activating cleavages 
independently of each other. Figure 5 presents SDS PAGE analysis of prothrombinase 
catalyzed reactions performed on rMZ-II (panel A) and rP2-II (panel B). Panel A shows 
the reaction performed in the absence of D5Q in lanes 1 – 9 and the reaction performed in 
the presence of D5Q, lanes 10 – 18, demonstrating the inhibition of the initial cleavage at 
Arg
320
. Panel B shows the prothrombinase catalyzed activation of rP2-II in the absence 
(lanes 1 – 9) and the presence of D5Q (lanes 10 – 18) and demonstrates that D5Q has 
little effect on the activating cleavage of prothrombin at Arg
271
. Densitometry scanning of 
SDS PAGE presented in figure 5 and SDS PAGE not shown are presented in table 2 and 
demonstrate the selective inhibition of D5Q on the activating cleavage at Arg
320
, when 
the reaction is catalyzed by prothrombinase. Although at high D5Q concentrations 
inhibition of initial activating cleavage at Arg
271
 is observed.  
 To assay the effect of the interaction of D5Q with prothrombin has on the fXa 
catalyzed activation of prothrombin activity assays monitored through the cleavage of a 
chromogenic substrate were performed on a D5Q titration. Figure 6 shows the titration of 
D5Q on the activity of a fXa catalyzed activation of prothrombin 50% inhibition occurred 
at a 12M D5Q concentration. However concentrations of D5Q as high as 48M were 
incapable of completely inhibiting thrombin formation by fXa. SDS PAGE analysis of 
the lipid-bound fXa catalyzed activation of prothrombin demonstrated a greatly 
accelerated rate of prothrombin consumption, but showed a delayed generation of 
thrombin. Figure 7 demonstrates the rapid consumption of prothrombin with the  
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Peptide 
Concentration (M) 
rMZ-II 
 
rP2-II 
 
0 3.7 + 0.6* 0.34 + 0.04 
10 NS**   
13   0.2 + 0.1 
35   NS 
 
 
 
 
 
 
 
 
 
 
  M 1   2    3  4   5   6  7   8   9     10 11 12 13 1415 16 17 18     M 1    2    3  4   5   6   7  8   9     10 11 12  13 14 15 16 17 18    
rMZ-II rP2-II 
B 
F1•2-A 
F1•2 
II 
P2 
CONTROL + DYDYQ CONTROL + DYDYQ 
Figure 3.5 – Analysis of prothrombinase catalyzed activation of recombinant 
prothrombin molecules in the absence and presence of DYDYQ. Reactions were 
performed using the recombinant prothrombin molecules rMZ-II and rP2-II which are 
only capable of being cleaved at Arg
320
 and Arg
271
 respectively. Lanes 1-9 and 10-18 
are aliquots that were removed before the addition of fXa and 1, 4, 6, 10, 20, 30, 45 
and 60 minutes after the addition of fXa. The table was generated through 
densitometry scanning and gives the rate of prothrombin consumption in the absence 
and the presence of DYDYQ for both of the respective recombinant prothrombin 
molecules. 
* The rates that are presented are moles consumed · s
-1
· mole fXa
-1
  
** NS, not significant consumption. 
Figure 3.5 
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Figure 3.6 
Figure 3.6 – DYDYQ titration against membrane-bound fXa catalyzed activation 
of prothrombin. Prothrombin (1.4M) was incubated with increased concentrations 
of DYDYQ for ten minutes before addition into a reaction mixture containing fXa. 
The initial velocity of the reactions were measured and compared to reactions 
performed in the absence of DYDYQ. All measurements were performed in triplicate 
using different protein and peptide preparations and error bars are representative of 
standard deviation. 
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Figure 3.7 – SDS PAGE analysis of membrane-bound fXa activation of 
prothrombin in the absence and the presence of DYDYQ. Plasma-derived 
prothrombin was incubated with DYDYQ or an equivalent volume of buffer for ten 
minutes before addition into a reaction mixture containing 2.5nM fXa. Panel A is the 
reaction that was performed in the absence of DYDYQ and panel B is the reaction that 
was performed in the presence of 24M DYDYQ. Lanes 1-19 are aliquots that were 
removed before the initiation of the reaction and 0.5, 1, 3, 5, 7, 10, 12, 15, 20, 30, 45, 
60, 75, 90, 105, 120, 150 and 180 minutes after the reaction was started. The 
prothrombin fragments are the same as described in figure 3 with the additional 
fragments being: P1, prethrombin 1 (residues 156 – 579) and F1, fragment 1 (residues 
1 – 155).  
Figure 3.7 
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accumulation of the prethrombin 2 intermediate, evident of initial activating cleavage 
occurring at Arg
271
. However the production of thrombin is greatly delayed as evident by 
the delayed appearance of the B-chain of thrombin, meaning the subsequent cleavage of 
the prethrombin 2/fragment 1·2 at Arg
320
 is strongly inhibited.      
 To evaluate the effects D5Q has on the individual activating cleavages 
independently in a fXa catalyzed reaction the recombinant prothrombin mutants rMZ-II 
and rP2-II were once again employed. Figure 8 shows SDS PAGE analysis of the fXa 
catalyzed activation of the recombinant prothrombin molecules in the absence and the 
presence of D5Q. Panel A shows the cleavage of the rMZ-II prothrombin mutant by 
lipid-bound fXa and demonstrates that the presence of D5Q (lanes 10-18) has little effect 
on the activating cleavage at Arg
320 
when compared to the control reaction performed in 
the absence of peptide (lanes 1-9). Panel B shows the consumption of the rP2-II 
prothrombin mutant by lipid-bound fXa (lanes 1-9) and demonstrates a greatly 
accelerated rate of the cleavage at Arg
271
 in the presence of 20M D5Q (lanes 10-18). 
Densitometry scanning of the SDS PAGE presented in figures 7 and 8 and additional 
SDS PAGE of reactions performed in the presence of different D5Q concentrations not 
shown are presented in table 3. A D5Q concentration of 48M accelerated the rate of 
plasma derived prothrombin consumption by lipid-bound fXa by 50-fold, while a lower 
concentration of D5Q (24M) accelerated the rate of rP2-II consumption by lipid-bound 
fXa 70-fold. Table 3 also demonstrates that D5Q has little effect on the rate of proteolysis 
at Arg
320
 as evident by the similar rate of rMZ-II consumption by lipid-bound fXa in the 
absence or presence of D5Q. 
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Figure 3.8 
Figure 3.8 – Analysis of the activation of the recombinant prothrombin molecules 
by membrane-bound fXa. Membrane-bound fXa was used in SDS PAGE monitored 
reactions with the two prothrombin mutants rMZ-II and rP2-II as substrates used in the 
reactions performed in the presence and absence of DYDYQ. Lanes 1-9 and 10-18 are 
aliquots of the reaction mixture that were pulled out before initiation of the reaction 
and 5, 15, 30, 60, 90, 120, 150 and 180 minutes after the addition of fXa into the 
reaction mixture. The prothrombin derived fragments are the same as explained in 
figure legend 3. 
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Peptide 
Concentration 
(M) 
Plasma-derived 
Prothrombin rMZ-II rP2-II 
    
0 0.06 + 0.03* 0.08 + 0.022 0.014 + 0.005 
12 2 + 0.3  0.3 + 0.09 
20  0.06 + 0.03 0.5 + 0.09 
24 3.1 + 0.2  1 + 0.4 
48 3 + 0.7   
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 
Table 3.2 – Rates of prothrombin consumption by membrane-bound fXa. 
Densitometry scanning of the SDS PAGE shown in figures 7 and 8 were performed to 
measure the rates of consumption of prothrombin and recombinant prothrombin 
mutants rMZ-II and rP2-II in reactions performed in the absence and presence of 
increasing concentrations of DYDYQ.  
*  Rates of prothrombin consumption are measured as moles consumed · s
-1
 · mole 
fXa
-1
.  
 79 
 Since the carboxyl-terminal portion of the heavy chain of fVa shares homology 
with the hirudin derived anti-coagulant peptide molecules, we next investigated the 
similarity of inhibition between D5Q and the hirudin derived peptides. It has been 
previously determined that the hirudin peptides’ interaction with thrombin enhances the 
ability of thrombin to cleave thrombin specific chromogenic substrates. To investigate the 
possibility that the interaction of D5Q has a similar effect on thrombin’s ability to cleave 
chromogenic substrates, D5Q and the hirudin peptides were incubated in the presence of 
thrombin before the addition of the chromogenic substrate S-2338. Figure 9 show that the 
interaction of the sulfated and non-sulfated versions of the hirudin peptides increases the 
rate of cleavage of S-2338, while the interaction of D5Q with thrombin does not enhance 
the observed rate. This indicates that the hirudin peptides ability to inhibit thrombin 
formation in activity assays monitored through cleavage of a chromogenic substrate are 
misleading, since a dual effect is observed. 
 To assay the ability of the hirudin peptides on the pathway to thrombin formation 
SDS PAGE of prothrombinase catalyzed activation of prothrombin were performed. 
Figure 10 shows the results generated when prothrombin was incubated in the absence 
and presence of 100M of the sulfated and non-sulfated versions of the hirudin peptides 
(panels B and C). Panel A shows the uninhibited reaction and demonstrates the optimal 
rate of thrombin generation by a prothrombinase catalyzed reaction. Panel B shows the 
reaction under the same conditions, but in the presence of 100M hir54-65(SO3
-
) and 
demonstrates approximately 50% inhibition, while panel D shows the same reaction as 
monitored through the cleavage of a chromogenic substrate and implies an increased rate 
of thrombin generation due to the increased activity of thrombin to cleave S-2238 in the  
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Figure 3.9 – Direct effect of peptides on thrombin’s cleavage of Spectrozyme TH. 
Thrombin (50nM) was incubated in the presence of DYDYQ, Hir
54-65
(SO3-), and 
Hir
54-65
 for ten minutes before addition of the chromogenic substrate, Spectrozyme 
TH. After five minutes incubation the optical density of the samples were read at 
405nm. All samples were performed in triplicate and error bars are representative of 
standard deviation.  
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Figure 3.10 
Figure 3.10 – SDS PAGE analysis of Hir54-65(SO3-) and Hir
54-65
 inhibition of 
prothrombinase catalyzed activation of prothrombin. Panel A is a control reaction 
performed in the absence of peptide. Panel B is a reaction performed in the presence 
100M hir54-65(SO3-). Panel C is a reaction that was performed in the presence of 
100M Hir54-65. Lanes 1-19 are representative of aliquots removed from the respective 
reaction mixtures before the addition of fXa and 20, 40, 60, 80, 100, 120, 140, 160, 
180, 200, 220, 240, 300, 360, 600, 1200, 1800 and 3600 seconds after the addition of 
fXa. Panel D is a measurement of the initial rates of the reactions shown in panels A-C 
that was measured through the cleavage of a chromogenic substrate specific for 
thrombin and compared to a thrombin standard for quantification. Error bars are 
representative of standard deviation and graph was generated using Prisma Graphing 
software. 
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Prothrombinase 
Prothrombin 
Consumption 
(moles 
consumed · s-
1 · mole fXa-1) 
Prothrombin 
Consumption 
(Percent of 
Control) 
Thrombin 
Formation (nMIIa 
Formed · min-
1 · nMfXa-1) 
Thrombin 
Activity 
(Percent 
Control) 
Control (no 
peptide) 26.1 + 1.2 100 1770.2 + 227 100 
Hir54-65(SO3-) 12.6 + 0.6 48.3 2549.3 + 331 144 
Hir54-65 1.5 + 1 5.8 135.3 + 80 7.6 
DYDYQ 0.07 + 0.2 0.3 60.3 + 26 3.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 
Table 3.3 – Comparison of densitometry scanning and activity based assays. SDS 
PAGE from figure 10 were subjected to densitometry scanning to determine the rate of 
prothrombin consumption. The rate of thrombin generation was determined through 
activity based assays monitoring thrombin generation through cleavage of a 
chromogenic substrate specific for thrombin. Comparison of the two methods of 
determining thrombin generation demonstrates the misleading nature of monitoring 
inhibition by the hirudin peptides using a chromogenic substrate specific for thrombin.  
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presence of 100M hir54-65(SO3
-
). Panel C shows the reaction performed in the presence 
of 100M Hir54-65 and demonstrates a greatly inhibited generation of thrombin, however 
initial cleavage still occurs at Arg
320
 as evident by the generation of fragment 1·2A. Panel 
D shows the rate of thrombin generation in the absence and presence of the hirudin 
peptides and D5Q as determined by an activity assay monitored through the cleavage of 
the chromogenic substrate S-2338, demonstrating the discrepancy of the inhibitory 
potential of the hirudin peptides when monitored in this fashion. Densitometry scanning 
of the SDS PAGE presented in figure 10 was performed to generate the rates of 
prothrombin consumption presented in table 3, establishing the discrepancy between the 
two ways of monitoring the inhibitory potential of the respective peptides.  
 Since the inhibition of the hirudin peptides on the generation of thrombin by 
prothrombinase has previously been shown to be optimal in the absence of a membrane 
surface, D5Q was next titrated against a fXa/fVa complex generated in the absence of 
PCPS. Figure 11 shows a similar inhibition response to D5Q concentration as compared 
to a titration of D5Q in the presence of a fully assembled prothrombinase complex 
assembled on a PCPS surface. This demonstrates a contrast between the inhibition of 
D5Q when compared to the hirudin peptides because the presence of a membrane surface 
has little influence on the inhibitory potential of D5Q on the fXa/fVa complex.  
 As a means of monitoring the effect that Hir
54-65
(SO3
-
) and D5Q has on the 
pathway to thrombin generation, reactions performed in the absence and presence of the 
respective peptides and monitored through SDS PAGE. Figure 12 consists of time 
courses of prothrombin activating reactions performed in the absence of a lipid bilayer 
catalyzed  by  fXa  (panel A), a  fXa/fVa  complex  (panel B),  a  fXa/fVa  complex in the  
 84 
 
 
 
 
 
 
 
 
 
 
 
M DYDYQ 
 
0 2 4 6 8 10 12 14 16 
0 
20 
40 
60 
80 
100 
Figure 3.11 
 
Figure 3.11 – DYDYQ titration of a fVa/fXa complex in the absence of PCPS. To 
assay the dependency of a membrane surface on the inhibitory potential of DYDYQ a 
complex of fVa/fXa was titrated with an increasing concentration of DYDYQ. 
Prothrombin (500nM) was incubated in the presence of increasing concentrations of 
DYDYQ for ten minutes before addition into a reaction mixture containing 10nM fXa, 
5nM fVa and 3M DAPA. Initial rates of thrombin generation were measured and 
reactions performed in the presence of DYDYQ were compared to reactions 
performed in the absence of peptide as a means of determining the percent inhibition 
due to the concentration of DYDYQ present. All reactions were performed in triplicate 
and error bars are representative of standard deviation. 
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Figure 3.12 – SDS PAGE analysis of fVa/fXa complex in the presence of DYDYQ 
and Hir
54-65
(SO3
-
). To monitor the effect of the peptides on the pathway to 
prothrombin activation in the absence of PCPS SDS PAGE was used to monitor 
reactions. Panel A is a control reaction catalyzed by fXa, in the absence of fVa. Panel 
B is a control reaction performed in the presence of a fXa/fVa complex. Panel C is a 
reaction catalyzed by a fXa/fVa complex performed in the presence of DYDYQ. Panel 
D is a reaction catalyzed by a fXa/fVa complex performed in the presence Hir
54-
65
(SO3
-
). Lanes 1-19 are aliquots that were removed from the reaction before the 
addition of fXa and 0.5, 1, 3, 5, 7, 10, 12, 15, 20, 30, 45, 60, 75, 90, 105, 120, 150 and 
180 minutes after the addition of fXa. The prothrombin derived fragments are the 
same as identified in figure 3.  
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presence of 92M D5Q (panel C) and a fXa/fVa complex in the presence of 100M 
Hir
54-65
(SO3
-
). Panel A shows the ability of fXa to activate prothrombin in the absence of 
PCPS, thrombin is slowly generated through initial cleavage occurring at Arg
271
 as 
evident by the generation of the prethrombin 2 intermediate. Panel B shows a greatly 
accelerated generation of thrombin due to the addition of fVa into the reaction mixture, 
however in the absence of the PCPS surface the initial activating prothrombin cleavage 
occurs at Arg
271
. The addition of Hir
54-65
(SO3
-
) (panel C) and D5Q (panel D) slows the 
generation of thrombin by the fXa/fVa complex at a rate similar to that observed by the 
fXa catalyzed reaction (panel A). 
 Prethrombin 1 is a naturally occurring derivative of prothrombin that is generated 
through proteolysis at Arg
155
 by thrombin or fXa and results in the generation of fragment 
1 (prothrombin residues 1 – 155) and prethrombin 1 (prothrombin residues 156 – 579). 
Activity assays measuring thrombin generation by prothrombinase in the absence and 
presence of Hir
54-65
(SO3
-
) and D5Q were performed using prethrombin 1 in the absence 
and presence of fragment 1. Figure 13 shows the percent activity of these reactions and 
demonstrates the inability of D5Q to inhibit prothrombinase catalyzed activation of 
prethrombin 1, while Hir
54-65
(SO3
-
) inhibited prethrombin 1 activation both in the absence 
and presence of fragment 1. The dissimilar inhibition of reactions performed with 
prethrombin 1 as a substrate, again suggest dissimilar interaction of the two peptides with 
prothrombin.  
 To monitor the pathways to thrombin production from the prethrombin 1 substrate 
in the absence and presence of fragment one and the effects of Hir
54-65
(SO3
-
) and the D5Q 
peptides  SDS  PAGE  was  performed.   Figure  14   show   reactions   performed   using  
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Figure 3.13 – Activity assays measuring prothrombinase catalyzed activation of 
prethrombin 1 in the absence and presence of fragment 1. The prothrombinase 
catalyzed activation of prethrombin 1 was monitored through the chromogenic 
substrate specific for thrombin, Spectrozyme TH. Reactions performed in the presence 
of the DYDYQ and Hir
54-65
(SO3
-
) were compared to control reactions performed in the 
absence of these peptides to determine the percent inhibition. Panel A shows the 
prothrombinase catalyzed activation of prethrombin 1 in the absence and the presence 
of DYDYQ and Hir
54-65
(SO3
-
). Panel B shows the prothrombinase catalyzed activation 
of prethrombin 1/fragment 1 in the absence and the presence of DYDYQ and Hir
54-
65
(SO3
-
). All reactions were performed in triplicate and error bars are representative of 
standard deviation. 
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Figure 3.14 – SDS PAGE analysis of prothrombinase catalyzed activation of 
prethrombin 1. Panels A and B are control reactions monitoring the activation of 
prethrombin 1 catalyzed by membrane-bound fXa (10nM) in the absence (panel A) 
and presence (panel B) of fragment 1. Panels C and D are prothrombinase (1nM fXa 
and 15nM fVa) catalyzed activation of prethrombin 1 in the absence (panel C) and 
presence (panel D) of fragment 1. Panels E and F are the same conditions as panels C 
and D, but in the presence of 92M DYDYQ. Panels G and H are the same conditions 
as panels C and D, but in the presence of 100M Hir54-65(SO3
-
). Lanes 1-19 are 
aliquots from the various reaction mixtures that were removed before the addition of 
fXa and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 30, 45, 60, 90 and 120 minutes after the 
addition of fXa. The prothrombin derived fragments are the same as identified in 
figures 3 and 7 with F2-A being fragment 2 covalently attached to the A chain of 
thrombin (residues 156 – 320).   
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prethrombin as a substrate in the absence and the presence of fragment 1. Panels A and B 
are control reactions catalyzed by fXa and demonstrate the insufficient generation of 
thrombin by lipid-bound fXa in the absence of fVa. Panels C and D are prothrombinase 
catalyzed reactions and show that in the absence of fragment 1 (panel C) both 
prethrombin 1 activating cleavages occur at similar rates. When fragment 1 is added into 
the reaction mixture (panel D) the initial cleavage occurs at Arg
320
, as evident by the 
occurrence of fragment 2A, with the sequential cleavage at Arg
271
 occurring at an 
accelerated rate. Though the consumption of prethrombin 1 by prothrombinase is slower 
in the presence of fragment 1, the generation of thrombin is faster when fragment 1 is 
present, because the subsequent cleavage is greatly accelerated. Panels E and F are 
reactions performed in the presence of 92M D5Q and demonstrate that D5Q does not 
inhibit prothrombinase catalyzed activation of prethrombin 1 in the absence (panel E) or 
the presence of fragment 1 (Panel F). Hir
54-65
(SO3
-
) inhibited both the prothrombinase 
catalyzed activation of prethrombin 1 in the absence (panel G) and presence of fragment 
1 (panel H) as indicated by the activity assay presented in figure 13 and the SDS PAGE 
presented in figure 14. 
 Densitometry scanning of the SDS PAGE presented in figure 14 was performed to 
determine the relative rates of prethrombin 1 consumption in the absence and presence of 
fragment 1 (Table 4)  as well as the relative rate of generation of the B-chain of thrombin 
(figure 15). Table 4 shows that the rate of prethrombin 1 consumption by prothrombinase 
is 16 ± 2.9 moles consumed · s
-1
 · mole fXa
-1
, while the rate of consumption of 
prethrombin 1 in the presence of fragment 1 is slower, being 11.1 ± 2.5 moles 
consumed · s
-1 
· mole fXa
-1
. However, when comparing the generation of the B-chain of   
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Enzyme/Inhibitor 
 
 
Prethrombin 1 
(moles consumed · s-
1 · mole fXa-1) 
Prethrombin 1 + 
Fragment 1 
(moles consumed · s-
1 · mole fXa-1) 
fXa alone (Control) 0.8 + 0.6 0.5 + 0.4 
Prothrombinase (control) 16 + 2.9 11.1 + 2.5 
Prothrombinase + DYDYQ 17.8 + 2.6 11.4 + 0.55 
Prothrombinase + Hir54-65(SO3-) 5.2 + 3.5 NS* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4 
Table 3.4 – Densitometry scanning of SDS PAGE measuring the consumption of 
prethrombin 1. Densitometry scanning was performed on the SDS PAGE shown in 
figure 14 and the rate of prethrombin 1 consumption determined.  
*NS, not significant consumption. The concentration of prethrombin 1 varied from 
15M at time 0 to ~12M following 2 hr incubation with prothrombinase in the 
presence of Hir
54-65
(SO3-).   
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Figure 3.15 – Generation of the B chain of thrombin in the absence and presence 
of fragment 1. Densitometry scanning of the prothrombinase catalyzed controls 
presented in figure 14 was performed to measure the generation of the B chain of 
thrombin. The results are presented as density of B-chain band (arbitrary units * 10
3
) 
verses time (minute) for the prothrombinase catalyzed activation of prethrombin 1 in 
the absence and the presence of fragment 1.  
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thrombin as shown in figure 15, it is demonstrated that prethrombin 1 is activated 
approximately 3-fold faster in the presence of fragment 1, with reversal of the initial 
cleavage occurring at Arg
320
 as evident by the generation of fragment 2A.      
 We next looked at the activation of prethrombin 2 (prothrombin residues 271 – 
579) in the absence and presence of fragment 1·2 (prothrombin residues 1 – 270) and 
fragments derived from fragment 1·2 and the inhibitory potential of the peptides Hir
54-
65
(SO3
-
) and D5Q on this substrate. Results from activity assays employing prethrombin 2 
(panel A), prethrombin 2 in the presence of fragment 1·2 (panel B), prethrombin 2 in the 
presence of fragment 1 (panel C), prethrombin 2 in the presence of fragment 2 (panel D), 
and prethrombin 2 in the presence of both fragment 1 and fragment 2 (panel E) as 
substrates in a prothrombinase catalyzed reactions are presented in figure 16. Once again 
we observed a dissimilar inhibition pattern between the Hir
54-65
(SO3
-
) and D5Q peptides. 
D5Q only inhibited the prothrombinase catalyzed reactions employing prethrombin 2 in 
the presence of fragment 1·2, Fragment 1 or fragment 1 in addition to fragment 2 (panels 
B, C and D respectively) as substrates demonstrating the necessity of the presence of 
fragment 1 for D5Q inhibition in the activation of prethrombin 2. While Hir
54-65
(SO3
-
) 
displayed inhibition in reactions using the substrates prethrombin 2, prethrombin 2 in the 
presence of fragment 1, prethrombin 2 in the presence of fragment 2 and prethrombin 2 in 
the presence of both fragment 1 and fragment 2 (panels A, C, D and E respectively).  
 SDS PAGE was employed to visualize the prothrombinase catalyzed activation of 
prethrombin 2 in the presence of fragment 1·2 and prethrombin 2 in the presence of both 
fragment 1 and fragment 2 separately. Figure 17 shows these reactions performed in the 
absence and in the presence of both the Hir
54-65
(SO3
-
) and D5Q peptides. Panels A-C  
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Figure 3.16 – Prethrombin 2 activity assays. Panel A shows the activity of a 
prothrombinase catalyzed activation of prethrombin 2 in the absence and presence of 
DYDYQ and Hir
54-65
(SO3
-
). Panel B shows the activity of a prothrombinase catalyzed 
activation of prethrombin 2/fragment 1·2 in the absence and the presence of DYDYQ 
and Hir
54-65
(SO3
-
). Panel C shows the activity of a prothrombinase catalyzed activation 
of prethrombin 2/fragment 1/fragment 2 in the absence and the presence of Hir
54-
65
(SO3
-
). Panel D shows the activity of a prothrombinase catalyzed activation of 
prethrombin 2/fragment 1 in the absence and presence of DYDYQ and Hir
54-65
(SO3
-
). 
Panel E shows the activity of a prothrombinase catalyzed activation of prethrombin 
2/fragment 2 in the absence and presence of DYDYQ and Hir
54-65
(SO3
-
). All reactions 
were performed in triplicate and error bars are representative of standard deviation.  
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Figure 3.17 – SDS PAGE analysis of prethrombin 2 activation in the presence of 
fragment 1·2. Fragment 1·2 was used before and after cleavage by fXa (to produce 
fragment 1 and fragment 2 non-covalently attached) in reactions monitoring the 
prothrombinase catalyzed activation of prethrombin 2 in the presence and absence of 
the respective peptides DYDYQ and Hir
54-65
(SO3
-
). Panels A-C and D-F are 
prothrombinase catalyzed activations of prethrombin 2 in the presence of fragment 1·2 
and in the presence of fragment 1 and fragment 2 respectively. Panels B and E are 
reactions performed in the presence of 76M DYDYQ and panels C and F are 
performed in the presence of 100M Hir54-65(SO3
-
). Panels A-C had aliquots removed 
from the reaction mixture before addition of fXa and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
12, 15, 20, 30, 45, 60 and 90 minutes after the addition of fXa. Panels D-F had 
aliquots removed from the reaction mixture before addition of fXa, fragment 1 and 
fragment 2 and 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 300, 360, 600, 
1200, 1800 and 3600 seconds after the addition of the fXa, fragment 1 and fragment 2 
mixture. The prothrombin derived fragments are the same as identified in figure 3 and 
7 with F2 being fragment 2 (residues 156-270).  
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show the results of the reaction using prethrombin 2 in the presence of fragment 1·2 as 
the substrate. Panel A shows the control reaction performed in the absence of any 
inhibitors and demonstrates the optimal rate of prethrombin 2 activation when fragment 
1·2 is present. As indicated by the activity assay presented in figure 16 when 76M D5Q 
is present (panel B) the consumption of prethrombin 2/fragment 1·2 and the generation of 
the B-chain of thrombin are delayed, while the presence of 100M Hir54-65(SO3
-
) (panel 
C) had no effect on either the consumption of prethrombin 2/fragment 1·2 or the 
generation of the B-chain of thrombin. Panels D-F demonstrate that 76M D5Q (panel E) 
inhibits prethrombin 2 activation in the presence of cleaved fragment 1·2 (reaction 
mixture contained both fragment 1 and fragment 2) at a rate similar to that of 
prethrombin 2/fragment 1·2 (panel E), while 100M Hir54-65(SO3
-
) strongly inhibited 
thrombin formation from prethrombin 2 in the presence of both fragment 1 and fragment 
2 it showed little inhibition in the activation of prethrombin 2/fragment 1·2. The ability of 
the Hir
54-65
(SO3
-
) peptide to inhibit the activation of prethrombin 2 was restored upon 
cleavage of fragment 1·2. 
 To directly assay the nonexclusive interaction of the two peptides we next studied 
the prethrombin 2 activation in the presence of fragment 1·2 in an activity based assay. 
Since the activation of prethrombin 2/fragment 1·2 by prothrombinase was inhibited by 
D5Q, but unaffected by Hir
54-65
(SO3
-
), if both peptides were interacting at the same site 
on the prethrombin 2/fragment 1·2 the Hir
54-65
(SO3
-
) would interfere with D5Q ability to 
inhibit this reaction. Increasing concentrations of Hir
54-65
(SO3
-
) were incubated in the 
presence of prethrombin 2/fragment 1·2 followed by titration with D5Q. Figure 18 shows 
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Figure 3.18 – DYDYQ titration of prethrombin 2 activation in the presence of 
fragment 1·2 and Hir
54-65
(SO3
-
). Prethrombin 2 was incubated in the presence of 
fragment 1·2 with increasing concentration of Hir
54-65
(SO3
-
) and then this ternary 
complex was titrated with increasing concentrations of DYDYQ. Results were 
standardized to a thrombin standard and graphed nMIIa · min
-1
 · nMfXa
-1
 verse the 
concentration of DYDYQ.  
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that the inhibitory potential of D5Q was not affected by the increased concentrations of 
the Hir
54-65
(SO3
-
) peptide suggesting a nonexclusive interaction of the two peptides. 
3.5 DISCUSSION 
A recent study stated that the carboxyl-terminal portion of the heavy chain of fVa 
was not involved in recognition of prothrombin, however the study clearly showed that 
the removal of this portion of fVa resulted in a 50% loss in the specific activity of the 
cofactor which is consistent with several previous studies which demonstrated the 
involvement of the carboxyl-terminal portion of the heavy chain of fVa in the recognition 
of prothrombin. It has also been suggested that the recognition of prothrombin by fXa is 
altered in the presence of fVa due to a prothrombin binding site present on fVa. We have 
previous shown that the pentapeptide D5Q inhibited prothrombinase in a competitive 
fashion by substrate depletion. In addition we demonstrated that D5Q did not interfere in 
the highly specific fVa/fXa interaction. The present study has explored the mode of 
inhibition of D5Q on prothrombinase catalyzed activation of all of the physiological 
relevant substrates derived from prothrombin. 
The present study demonstrated that the interaction of D5Q with prothrombin 
resulted in the specific inhibition of cleavage at Arg
320
 by prothrombinase. Prethrombin 2 
in the presence of fragment 1·2 is the naturally occurring intermediate of a membrane-
bound fXa catalyzed activation of prothrombin (pathway 1 in figure 1) and consequently 
is a substrate that would naturally occur as a response to an injury, since fXa is generated 
before fVa. Therefore prothrombinase would naturally recognize the prethrombin 
2/fragment 1·2 intermediate, since the generation of prothrombinase occurs after the 
generation of fXa and consequently after some prothrombin has been converted to the 
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prethrombin 2/fragment 1·2 intermediate. Interestingly, D5Q was incapable of inhibiting 
other naturally occurring derivatives of prothrombin. 
Surprisingly, the interaction of D5Q with prothrombin greatly accelerated the 
ability of lipid-bound fXa to cleave the zymogen prothrombin at Arg
271
 to produce the 
intermediate prethrombin 2/fragment 1·2. The subsequent activating cleavage at Arg
320
 
by lipid-bound fXa was greatly inhibited due to the interaction of the intermediate with 
D5Q resulting in a greatly decreased generation of thrombin by fXa. The interaction of 
D5Q with prothrombin or the prethrombin 2/fragment 1·2 intermediates resulted in a 
greatly decreased rate of thrombin generation by both prothrombinase and fXa in the 
absence of fVa. However D5Q had little inhibitory effect on the activation of other 
prothrombin derived fragments or on the activation of prethrombin 2 in the absence of 
fragment 1. The prothrombinase catalyzed activation of the intermediates prethrombin 1 
or active-site blocked meizothrombin (data not presented) were unaffected by the 
presence of D5Q.            
Since the carboxyl-terminal region of the heavy chain of fVa shares homology 
with the hirudin derived peptides, we initially postulated that D5Q probably interacted 
with prothrombin in a fashion similar to the interaction of Hir
54-65
(SO3
-
) with prothrombin. 
However the present study demonstrates that D5Q and Hir
54-65
(SO3
-
) have dissimilar 
inhibition patterns and suggests that the interaction of D5Q with prothrombin and the 
derivatives of prothrombin occur in a manner independent of the interaction of Hir
54-
65
(SO3
-
) with prothrombin or the prothrombin derivatives. Further studies directly 
identifying the specific binding site of D5Q on prothrombin and its derivatives need to be 
performed to establish this, though presently all experimental data imply a distinct 
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binding site for D5Q. Finally it is interesting to note that the ability of Hir
54-65
(SO3
-
) to 
inhibit the activation of the naturally occurring derivatives of prothrombin demonstrate 
almost an exact opposite inhibition pattern as D5Q. While both Hir
54-65
(SO3
-
) and D5Q 
display strong inhibition on prothrombin, Hir
54-65
(SO3
-
) does not reverse the cleavage 
pattern observed. Hir
54-65
(SO3
-
) strongly inhibit the activation of prethrombin 1, and 
prethrombin 2 in the absence of fragment 1·2, while D5Q had little effect in these 
reactions. In contrast D5Q strongly inhibited the prothrombinase catalyzed activation of 
prethrombin 2 in the presence of fragment 1·2 while Hir
54-65
(SO3
-
) showed little ability to 
inhibit this reaction.  
In conclusion, the present study has demonstrated that a synthetic pentapeptide 
derived from the carboxyl-terminal portion of the heavy chain of fVa, strongly inhibits 
the activation of prothrombin by both prothrombinase and lipid-bound fXa by selectively 
inhibiting the activating cleavage that occurs at Arg
320
. While D5Q demonstrated little 
ability to inhibit the activation of most prothrombin derived intermediates, it did strongly 
inhibit the most commonly generated intermediate, prethrombin 2/fragment 1·2. While 
the sequence D5Q occurs within a region of fVa that shares homology with the well-
established anticoagulant peptide molecule derived from hirudin, the interaction between 
prothrombin with D5Q or Hir
54-65
(SO3
-
) are probably different and result in different 
inhibition pattern when the two molecules (i.e. D5Q and Hir
54-65
(SO3
-
)) are compared. 
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CHAPTER IV 
THE AMINO-TERMINAL PORTION OF THE LIGHT CHAIN OF FACTOR Va 
INTERACTS WITH FACTOR Xa IN THE PROTHROMBINASE COMPLEX 
4.1 ABSTRACT 
Prothrombinase assembly occurs when activated factor V (fVa) interacts with activated 
factor X (fXa) on a phospholipid bilayer in the presence of divalent metal ions. Previous 
studies have shown that the A3 domain from the light chain of fVa contains an interactive 
site for fXa which is necessary for proper prothrombinase assembly and function. To 
determine which amino acids present within the A3 domain of the light chain of fVa are 
involved in recognition of fXa we have used overlapping synthetic peptides 
representative of residues 1546-1612 of the A3 domain to screen their ability to inhibit 
prothrombinase activity in a fXa dependent manner. The peptide representative of the 13 
amino acids spanning residues 1546 through 1558 strongly inhibited prothrombinase 
activity demonstrating an IC50 of 50M. To investigate the individual amino acids 
involved in recognition of fXa overlapping synthetic pentapeptides from this region were 
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used in further flourometeric studies. Peptides which included amino acids representative 
of residues 1553-1558 of the A3 domain were capable of inhibited prothrombinase 
activity. To further investigate the hypothesis that this region is important in 
prothrombinase function a recombinant fV mutant was generated deleting residues 1549 -
1558 (fVa
dS13A
). The fVa
dS13A
 mutant demonstrated a greatly decreased specific activity 
in clotting based assays. Prothrombinase assembled with fVa
dS13A
 showed a 5 fold 
increase in the apparent Kd value for the fVa/fXa interaction and a 50% reduction in the 
overall rate of the enzyme. The present study defines a potential fXa interactive site 
present within residues 1546-1558 of the A3 domain of fVa.                    
4.2 INTRODUCTION 
 The timely repair to vascular injury is dependent on the efficient activation of 
thrombin by the enzymatic complex prothrombinase. Prothrombinase is composed of 
activated fX, associated with activated fV in the presence of calcium ions on a 
phospholipid bilayer (1). The enzymatic component, fXa, is capable of activating the 
zymogen prothrombin through two sequential proteolytic cleavages occurring after 
residues Arg
271
 and Arg
320
 (2). The inclusion of fVa in the prothrombinase complex 
reverses the order of these two activating cleavages and accelerates the generation of 
thrombin by five orders of magnitude, thus the formation of the prothrombinase complex 
is necessary for the timely activation of prothrombin (3-5).  
 The assembly of the prothrombinase complex is dependent on the activation of 
both clotting factors X and V. Activation of fX occurs through a single proteolytic 
cleavage catalyzed by either the intrinsic or the extrinsic Xase complexes (6). The 
catalytic activity of fXa is not enhanced by the zymogen fV until it has been converted to 
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its active form. The activation of fV is catalyzed by either fXa or thrombin and occurs 
through three sequential cleavages occurring after residues 709, 1018 and 1545 (7). The 
activation of fVa results in the release of an interconnecting B-domain and a fully 
functional cofactor molecule composed of by an amino-terminally derived heavy chain 
non-covalently associated to a carboxyl-terminally derived light chain (8). The heavy 
chain of the fVa is composed of by residues 1-709 and is involved in the recognition of 
both fXa and prothrombin, while the light chain is composed of by residues 1546-2196 
and is involved in recognition of both fXa and the membrane surface (8-13). 
The A3 domain from the light chain of fVa has been implicated many times in 
binding fXa. Activity assays performed in the presence of a monoclonal antibody 
recognizing an epitope in this region of the light chain showed a decrease interaction 
between fVa and fXa (8). A decrease in the ability of fVa to interact with fXa was also 
demonstrated by mutagenic studies involving site-directed glycosylation of Thr residues 
1683 (14). Another study used the enzymes cathepsin G and elastase to activate fV to a 
fVa-like species, both resulted in a cofactor molecule with a truncated heavy chain and an 
elongated light chain having a 15 and 8 fold decrease affinity for fXa respectively. 
Further treatment of these molecules with thrombin restored a normal light chain and 
consequently the affinity for fXa (15). Site directed mutagenesis at Arg
1545
 showed 
similar results demonstrating the necessity of a fully formed light chain as a prerequisite 
for an optimal interaction between fVa and fXa (16). Results obtained using an enzyme 
from the snake venom of Naja nigricollis nigricollis to activate fV generating a fVa-like 
molecule composed of a heavy chain of Mr 100,000kDa and a light chain with a Mr of 
80,000kDa displayed a 20 fold increase in the Kd for the fVa/fXa interaction. Further 
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cleavage of this molecule with thrombin produced a normal light chain and restored the 
affinity of fVa for fXa (17). Taken together all of the above experiments show a strong 
dependency of the fVa/fXa association on proper exposure of the A3 domain of the light 
chain of fVa. 
4.3 EXPERIMENTAL PROCEDURES 
 Materials, reagents and proteins. L--phosphatidylserine (PS) and L--
phosphatidylcholine (PC) were purchased from Avanti Polar Lipids (Alabaster, AL) and 
prepared as previously described (18) followed by quantification by assaying for 
phosphorus. The chromogenic substrate Spectrozyme-TH was purchased from America 
Diagnostica, Inc (Greenwich, CT). Human -thrombin, prothrombin, human fXa and the 
fluorescent thrombin inhibitor dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (Dapa) 
were purchased from Hematologic Technologies, Inc. (Essex Junction, VT). The 
monoclonal antibody hFV1 coupled to Sepharose, and the two monoclonal antibodies 
against factor V (against the heavy and the light chains respectively, HFVHC#17 and 
HFVLC#9) were provided by Dr. Kenneth G. Mann (Department of Biochemistry, 
University of Vermont, Burlington, VT). Diisopropyl fluorophosphates (DFP), O-
phenylenediamine dihydrochloride (OPD), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Trizma, Coomassie Blue R-250 and factor V-
deficient plasma were purchased from Sigma. Polyethylene glycol (Mr 8000) was 
purchased from J. T. Baker (Danvers MA). The secondary anti-mouse and anti-sheep IgG 
coupled to peroxidase were purchased from Southern Biotechnology Associates Inc. 
(Birmingham, AL). The chemiluminescent reagent ECL
+
 was purchased from Amersham 
Biosciences. The thromboplastin reagent (recomboplastin) used in clotting assays was 
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purchased from Beckman (Fullerton, CA). The cDNA encoding fV was purchased from 
American Type Tissue Collection (ATCC 40515 pMT2-V, Manassas, VA). All 
restriction Enzymes were purchased from New England Biolabs (Beverly, MA). Human 
fV and fVa were purified and concentrated using methodologies previously described 
employing the monoclonal antibody hFV#1 coupled to sepharose and heparin-sepharose 
respectively (19-21). 
  The recombinant fV light chain mutant used throughout this series of experiments 
was generated using mutagenic primers. The fV deletion mutant (rfV
dS13A
) was designed 
to remove the amino acids represented by the S13A peptide (The deleted amino acids 
were residues 1549-1558) and was generated using the primers 
5'GCAGCATGGTACCTCCGCAGCAACAATGAAGAAATATCCTGGGATTATTCA
G-3' and 5'-CTGAATAATCCCAGGATATTTCTTCATTGTTGCTGC-
GGAGGTACCATGCTGC-3'. These mutagenic primers were used in PCR employing 
pMT2-fV plasmid as a template and the product was subjected to DpnI digestion before 
transformation into chemically competent bacteria. Colonies were selected and purified 
plasmids were screened for the presence of the desired mutation by DNA sequencing.  
Purification and Determination of Concentration of rfV Mutants – The 
recombinant proteins were generated as previously described (22). Cultured VP-SFM 
medium of WT and rfVa
dS13A
 concentrated using a vivaflow 50 connected to a masterflex 
L/S to a final volume of approximately 10ml followed by washing with a trizma (20mM 
trizma base) buffered saline solution with 5mM Ca
2+
 at pH 7.40. Purification was 
performed on 1 ml columns of HFV-1 antibody coupled to sepharose and eluted using 
2M NH3Cl at a pH 7.40 and concentration by centrifugation on YM-30 centricons 
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followed by three consecutive washes with trizma buffered saline solution in the presence 
of 5mM CaCl2. Aliquots of purified protein were stored at -80°C for future use. Protein 
concentration were determined using spectrophotemetry and an extension coefficient of 
0.96 (1%280nm) followed by ELISA (as previously described) to independently confirm 
the concentration (22).  Protein purity was determined by coomassie and silver staining of 
SDS-PAGE.   
 Activation of Recombinant Molecules – Throughout the present study activation 
of all recombinant fV molecules was accomplished by incubation of the purified 
molecules with thrombin at a 1/100 (enzyme to substrate) ratio for ten minutes at 37°C. 
Addition of 2mM DFP, a specific serine protease inhibitor, stopped the reaction, followed 
by a 30 minute incubation on ice. Previous experiments showed that these conditions 
assure complete activation of the cofactor with minimal thrombin degradation to the 
activated molecule. However in all cases western blots using monospecific antibodies 
that recognize the heavy and light chains respectively was performed to assure minimal 
degradation of the activated protein. 
 Determining the Kinetic Parameters Governing Mutant Molecules – Assays 
measuring the kinetic parameters consisted of prothrombinase assembled in the presence 
of prothrombin and measured the appearance of the product thrombin by the secondary 
event of cleavage of a chromogenic substrate. This is a discontinuous assay measuring 
the initial velocity of the reaction through monitoring several time points within the first 
two minute of the reaction. The determination of the affinity of fVa for fXa was 
measured directly through titrating a limiting fXa concentration with increasing 
concentrations of fVa to determine the apparent Kd value for the fXa/fVa interaction. 
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Assays were performed in 96 well plates and measured the initial velocities of product 
formation from the different concentrations of the titrant (fVa). Time points from each of 
the different reactions were stopped by addition into a buffer containing EDTA. Prism 
graphing software was used to interpret the data and generate kd values for the titrations. 
In all cases mutants were compared to wild type protein and measurements were done in 
triplicate with different protein purifications. The obtained kd values were used to 
determine proper ratios of fVa mutants to fXa to ensure similar concentrations of the 
assembled prothrombinase complex to be used in the prothrombin titrations. Prothrombin 
titrations were performed to determine the apparent km values for prothrombinase 
assembled with rfVa
dS13A
. Prothrombin titrations were performed in 96 well plates and 
reactions consisted of a limiting fXa concentration in the presence of saturating fVa 
concentrations as determined by kd values obtained from the fVa titrations. Prism 
graphing software was used to determine measurements of the initial velocity of the 
varied prothrombin concentrations and to generate a secondary graph measuring 
maximum velocity and km of the various reactions.   
Effects of Mutant Molecules in Prothrombin Activation. – Since prothrombin 
activation consists of two ordered sequential cleavages resulting in intermediates with 
enzymatic activity, meizothrombin, and without enzymatic activity, prethrombin 2, 
deficiency in assays measuring thrombin formation monitored through a chromogenic 
substrate may not show the reason for the deficiency. Monitoring prothrombin 
consumption using SDS PAGE allows determination of cleavage patterns. 
Prothrombinase assembled with rfVa
dS13A
 were used in prothrombin activating reactions 
subjected to SDS-PAGE followed by coomassie blue staining. Aliquots of reaction 
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mixtures were placed in 0.2M acetic acid to stop the reaction followed by preparation for 
SDS-PAGE as previously described (23).   
Clotting Times Measurements – One stage and two stage measurements of time to 
clot formation were performed with identical concentrations of all the fVa molecules 
used throughout this study. One-stage clotting assay were performed by the addition of 
the procofactor (fV) into fV deficient plasma, while two stage clotting assays were 
performed with the activated cofactor (fVa) being added to fV-deficient plasma. In both 
cases coagulation was initiated by the addition of thromboplastin reagent and the time to 
clot formation measured. Recombinant molecules unable to accelerate fibrin clot 
formation in fV-deficient plasma to the same degree as wild type fVa are considered to 
be functionally defective. All purified protein preparations were assayed in triplicate in 
this manner.  
Fluorescence Measurements of Thrombin Generation – Thrombin formation was 
analyzed using the fluorescent inhibitor DAPA on a PerkinElmer LS-50B Luminescence 
spectrophotometer. Reactions were performed in the presence and absence of the various 
peptides by incubating a final concentration of 10nM fXa with the various concentrations 
of the different peptides for ten minutes at ambient temperature before addition into 
reactions mixture composed of 4nM fVa, 20M PCPS, 350nM prothrombin in a HEPES 
buffered saline solution. Reactions were monitored using an excitation wavelength at 
280nm and an emission wavelength of 520nm. All reactions performed in the presence of 
peptides were compared to reactions performed in the absence of peptides to measure the 
percent inhibition.         
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4.4 RESULTS 
 Since previous studies demonstrated the possibility that the interaction of fXa 
with the light chain of fVa involved the amino-terminal region of the A3 domain (8,14-
17), initial studies were performed using overlapping synthetic decapeptides 
representative of the A3 domain sequence to screen their ability to inhibit prothrombinase 
activity. Figure 1 shows a schematic of the synthetic peptides used throughout this study 
with reference to the sequence they represent and their chosen nomenclature. 
Fluoremetric analysis of thrombin generation by prothrombinase in the presence of the 
various peptides is presented in figure 2 and shows only two of the screened peptides 
significantly inhibited thrombin generation. Both S13A and LCD3, peptides 
representative of residues 1546-1558 and 1569-1578 respectively, inhibited thrombin 
generation by prothrombinase in a manner similar to the activity of fXa alone, implying a 
possible diminished interaction between fXa and fVa. S13A was the stronger of the two 
inhibitory peptides and is representative of the amino-terminal region of the light chain of 
fVa, a region conserved through evolution as shown in figure 3. All of the other peptides 
from this region had little to no inhibitory effect on the activation of prothrombin by 
prothrombinase.   
 Since S13A showed the strongest inhibition in the initial screening of this region, 
we next designed a series of overlapping pentapeptides from the sequence of S13A. 
Figure 4 is a schematic showing the next series of peptides used throughout this study 
with their sequence compared to that of S13A and their assigned nomenclature on the 
right of their sequence. A follow up fluoremetric study presented in figure 5 
demonstrated   only  the   latter  three   of  these  five   pentapeptides  had   any  inhibitory  
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1546
SNNGNRRNYYIAAEEISWDYSEFVQRETDIEDSDDIPEDTTYKKVVFRKYLDSTFTKRDPRGEYEEH
1612
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TFTKRDPRGE 
DPRGEYEEH 
Figure 4.1 
Figure 4.1 – Synthetic peptides generated for screening light chain’s ability to 
associate with fXa. Figure 1 shows a schematic of the synthetic peptides used 
throughout this study. The corresponding sequence of the light chain of fVa is 
presented at the top of the figure along with the corresponding residue numbers. The 
nomenclature used throughout the study for these peptides are presented at the left-
side of the schematic, while the actual sequences are shown under the sequence from 
the light chain of fVa they represent.   
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Figure 4.2 – The synthetic peptides abilities to inhibit prothrombinase. The synthetic 
peptides introduced in figure 1 were incubated with 10nM fXa before addition into a 
reaction mixture composed of 4nM fVa, 20M PCPS, 10M Dapa and 350nM 
prothrombin. Reactions were monitored through fluorescence as described in the 
experimental procedures section. Figure 2 shows the control reactions catalyzed by the 
prothrombinase complex and lipid-bound fXa followed by reactions catalyzed by 
prothrombinase assembled in the presence of the 100M of respective peptides. 
Reactions performed in the presence of the various peptides were compared to 
reactions performed in the absence of peptide as a means of calculating percent 
control. 
Figure 4.2 
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HUMAN         SNN GNR RN YY IAA  
BOVINE         SNT GNR KY YY IAA  
MOUSE         GHG GHK KF YY IAA  
PORCINE      SNN GNR RN YY IAA   
Figure 4.3 
Figure 4.3 – A comparison of the amino-terminal sequence of the light chain of 
fVa from different species. The sequence of the region represented by the S13A 
peptide from bovine, mouse and porcine is compared to the human sequence and 
demonstrates strong homology. 
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SNNGNRRNYYIAA            S13A 
SNNGNRR                                S7R 
                  NYYIAA                   N6A  
                  NFFIAA                    N6A (FF) 
 
SNNGN               S5N 
     NGNRR              N5R 
           NRRNY             N5Y 
                 RNYYI             R5I 
                      YYIAA            Y5A 
Figure 4.4 
Figure 4.4 – Synthetic peptides used in determining the binding site present 
within the light chain of fVa for fXa. Schematic showing the peptides used for the 
determination of the binding site present within the light chain of fVa for fXa. S13A is 
a synthetic peptide which strongly inhibits thrombin generation in a prothrombinase 
catalyzed reaction that is representative of the amino-terminal region of the light chain 
of fVa (residues 1546 – 1558). All other peptides used are shorter derivatives of S13A 
and are aligned under the sequence for S13A. 
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Figure 4.5 
Figure 4.5 – Inhibition study using overlapping pentapeptides representative of 
the amino-terminal region of the light chain of fVa. Overlapping pentapeptides 
representative of amino acid residues 1546 – 1558 of the light chain of fVa were 
synthesized to screen their ability to inhibit thrombin activation by prothrombinase. 
Reaction mixtures consisting of 4nM fVa, 700nM DAPA, 10M PCPS and 350 nM 
prothrombin were initiated with 10nM fXa (final concentration in the reaction) that 
was incubated for 10 minutes in the presence of 150M of the respective peptides as 
indicated in the figure. Initial velocities were measured throughout the first 30 seconds 
of the reaction and compared to a standard reaction performed in the absence of 
peptide to determine the percent inhibition. All reactions were performed in triplicate 
and error bars are representative of standard deviation. 
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ability on thrombin generation by prothrombinase. The three pentapeptides N5Y, R5I and 
Y5A all showed the ability to inhibit thrombin generation with Y5A being the strongest 
inhibitor of the series of overlapping S13A derived peptides. Y5A demonstrated an IC50 
of 150M and shows 100% conservation of the compared sequences presented in figure 3.  
Since peptide inhibition of prothrombinase only occurred when amino acids 
representative of residues 1553-1558 were used and no inhibition was observed with 
peptide sequences representative of amino acids 1546-1552, two additional peptides were 
generated from the S13A sequence. As shown in figure 4 the two peptides representative 
of amino acids 1546-1552 and 1553-1558 were S7R and N6A respectively. When S7R 
and N6A were titrated into a prothrombinase catalyzed activation of prothrombin and 
monitored by fluoremeter, N6A displayed a similar inhibition pattern as compared to 
S13A. This suggested that the amino acid sequence from 1553-1558 was involved in the 
observed inhibition, so this sequence was then altered as a control for the specificity of 
this sequence. The charge of the pentapeptide was weakened by the removal of the 
charges from two amino acids, two tyrosine residues were conservatively substituted to 
phenylalanines as depicted in figure 4. The N6A(FF) peptide lost the inhibitory effect 
demonstrated by the unaltered sequence of the N6A peptide as shown in figure 6 (opened 
triangles). 
Since all of the peptide studies suggested that the amino-terminal region of the 
light chain of fVa was involved in the recognition of fXa, we next studied the possibility 
that this region of fVa was involved in fXa recognition through recombinant methods. A 
recombinant molecule deleting the region represented by the S13A peptide was generated  
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Figure 4.6 
Figure 4.6 – Titration of S13A, S7R, N6A(WT) and N6A(FF) in a 
prothrombinase catalyzed activation of prothrombin. Increasing concentrations of 
the synthetic peptides S13A, S7R, N6A(WT) and N6A(FF) were incubated in the 
presence of 10nM fXa for 10 minutes before addition into a reaction mixture 
composed of 4nM fVa, 700nM DAPA, 10M PCPS, and 350nM prothrombin. 
Reactions were monitored through the fluorescence properties of DAPA and 
compared to standards performed in the absence of peptides to determine the percent 
inhibition. All reactions were performed in triplicate and error bars are representative 
of standard deviation.   
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as described in the material and method section. The recombinant fVa molecule missing 
residues 1546-1558 (rfVa
dS13A
) was activated by incubation with thrombin and subjected 
to SDS PAGE followed by Western blotting. Figure 7 shows a Western blot using 
monoclonal antibodies which recognizing the heavy and light chains of rfVa
dS13A
 and 
rfVa
WT
. Upon activation both the rfVa
dS13A
 and rfVa
WT
 molecules generated the heavy 
and light chains of the active cofactor, however the rfVa
dS13A
 molecule always produced 
a fragment present at 220,000kDa that persisted even after extended incubation with 
thrombin.        
We next studied the ability of prothrombinase assembled with the rfVa
dS13A
 
molecule to activate prothrombin and monitored the reaction through SDS PAGE as 
presented in figure 8. When reactions catalyzed by prothrombinase assembled with the 
rfVa
dS13A
 (panel B) are compared to reactions catalyzed by prothrombinase assembled 
with plasma derived fVa (panel A) an approximately 50% reduction in the ability to 
activate prothrombin is observed. When the impaired function of prothrombinase 
assembled with the rfVa
dS13A
 molecule is directly compared to the inhibition of the S13A 
peptide on prothrombinase assembled with fVa (panel C) similar rates are observed. 
Densitometry scanning of the SDS PAGE presented in figure 8 was performed to produce 
the rates of prothrombin consumption presented in table 1. As shown, the rate of 
prothrombin consumption in the presence of saturating concentrations of S13A, 4.5 
moles consumed·s
-1
·mole of fXa
-1
, was comparable to the rate of prothrombin 
consumption by prothrombinase assembled with the recombinant fVa
dS13A
 molecule, 5.7 
moles consumed·s
-1
·mole of fXa
-1
. 
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Figure 4.7 
Figure 4.7 – Western blot of recombinant molecules. The monoclonal antibodies 
hfV#9 and hfV#17 were used to detect both the heavy and light chains of the 
rfVa
WT
 and rfVa
dS13A 
molecules. The positions of both the heavy and light chains of 
fVa are indicated along with a partial activation fragment present in the rfVa
dS13A
 
sample 
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Figure 4.8 – SDS PAGE analysis of prothrombinase catalyzed activation of 
prothrombin in the absence and presence of S13A and prothrombinase 
assembled with rfVa
dS13A
. Panels A-C are prothrombinase catalyzed reactions that 
were performed under the following conditions: 10nM fVa species (panel A used 
rfVa, panel B used rfVa
dS13A
 and panel C used plasma derived fVa in the presence of 
100M S13A), 0.5nM fXa, 10M DAPA, 20M PCPS and 1.4M prothrombin. 
Reactions were initiated by the addition of fXa and aliquots were removed for SDS 
PAGE before the addition of fXa and 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 
220, 240, 300, 360, 600, 1200, 1800 and 2400 seconds after the addition of fXa.   
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Moles consumed·s-1·mole of fXa-1 
WT fVa
dS13A
 fVa + S13A 
12.6 5.7 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 
Table 4.1 – Densitometry scanning of SDS PAGE presented in figure 8. 
Densitometry scans for the three SDS PAGE presented in figure 8 were performed to 
determine the rate of prothrombin consumption by prothrombinase assembled with the 
rfVa
dS13A
 mutant and prothrombinase in the presence of 100M S13A. Scanning of the 
control reaction of prothrombinase assembled with rfVa
WT
 was also performed as a 
control. The rates shown are moles of prothrombin consumed per second per mole of 
fXa present in the reaction. 
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To explore the possibility that the inhibition pattern observed in figure 8 is due to 
a decrease affinity of rfVa
dS13A
 for fXa, a limiting concentration of fXa was titrated 
against an increasing concentration of the rfVa
dS13A
 mutant. Figure 9 shows the graph 
generated when the rfVa molecules were titrated against 15pM fXa. The titrations was 
carried out to 20nM rfVa concentrations, however the graph only shows the titrations to 
10nM. As shown, both titrations were carried out until increasing the concentration of the 
different recombinant cofactor molecules no longer significantly increased the rate of 
thrombin production over the previous concentrations implying a maximum rate of 
thrombin production had been obtained. The determined apparent Kd values obtained 
from the fVa titrations are presented in table 2. The rfVa
dS13A
 apparent Kd value of 1.915 
is 5.5 times higher than the rfVa
WT
 apparent Kd value suggesting a greatly weakened 
interaction between the rfVa
dS13A
 and fXa when compared to the rfVa
WT
 affinity for fXa.  
The rfVa
dS13A
 apparent Kd value was used to determine the saturating 
concentration of rfVa
dS13A
 used in the prothrombin titration presented in figure 10. A 
concentration of 20nM rfVa
dS13A
 was used to ensure that more than 95% of the fXa in 
solution was associated with the rfVa
dS13A
 molecule for the prothrombin titration. This 
allowed the determination of apparent Km and Kcat values for prothrombinase assembled 
with the rfVa
dS13A
, because the concentration of the enzymatic complex formed rather 
than the concentration of the constituents of the enzymatic complex were measured. 
Figure 10 presents the graphs generated from the prothrombin titration of prothrombinase 
assembled with the rfVa
WT 
and the rfVa
dS13A
 cofactor molecules respectively. Initial rates 
of thrombin formation over the various prothrombin concentrations used in the reactions 
were graphed to determine the maximum velocity of the respective enzymes. Table 2  
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Figure 4.9 
Figure 4.9 – fVa titration with prothrombinase assembled with rfVaWT and 
rfVa
dS13A
. The determination of the kd values for the rfVa
dS13A
 was performed through 
titrating increasing concentrations of rfVa
dS13A
 into a prothrombinase catalyzed 
activation of prothrombin. Reaction conditions used were: 0.015nM fXa, 10M 
DAPA, 20M PCPS and 1.4M prothrombin. Titrations were performed in triplicate 
using different protein preparations and compared to titrations performed using 
rfVa
WT
. Error bars are representative of standard deviation. The empirically derived kd 
values are presented in table 2. 
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Figure 4.10 
Figure 4.10 – Prothrombin titrations performed in the presence of fully saturated 
prothrombinase assembled with rfVa
WT
 and rfVa
dS13A
. The determination of the 
kinetic parameters governing rfVa
dS13A
 was performed through titrating fully 
complexed prothrombinase assembled with rfVa
dS13A
 with increasing concentrations 
of prothrombin. Reactions conditions for the titrations were: 0.5pM fXa, 10M 
DAPA, 20M PCPS and 20nM rfVadS13A for the prothrombinase assembled with 
rfVa
dS13A
 and 10nM rfVa
WT
 for the prothrombinase assembled with the wild type 
cofactor. Initial velocities were monitored through the chromogenic substrate S-2238 
and compared to a thrombin standard for quantification. The empirically derived 
kinetic values are presented in table 2. 
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  Kd 
(nM) 
Km 
(M) 
Kcat 
(min
-1
) 
    rfVa
WT
 
0.3500 0.2681 2002 
    rfVa
dS13A
 
1.915 0.3724 1136 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 
Table 4.2 – The apparent kinetic constants as derived from the titrations 
presented in figures 9-10. The titrations presented in figures 9 and 10 were analyzed 
using Prisma 2.01 Graphing software to generate the kinetic values presented in table 
2.   
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shows the apparent Km and Kcat values generated from the prothrombin titration 
presented in figure 10. The apparent Km value was not significantly altered when 
prothrombinase was assembled with the rfVa
dS13A
 as compared to prothrombinase 
assembled with rfVa
WT
, as evident by the respective values; 0.3724M and 0.2681M. 
However the Kcat of the reaction for the prothrombinase assembled with rfVa
dS13A
 was 
50% reduced, demonstrating that the weakened interaction of the rfVa
dS13A
/fXa complex 
resulted in a defective enzymatic complex which could not be corrected for by increasing 
the concentration of the rfVa
dS13A
 molecule. 
4.5 DISCUSSION    
 The present study strongly suggests, through synthetic peptide analysis and 
recombinant mutagenesis, that amino acid residues 1546-1558 from the light chain of fVa 
are crucial for fXa recognition and thus prothrombinase assembly. The synthetic peptide 
S13A, representative of residues 1546-1558 strongly inhibited prothrombinase ability to 
generate thrombin. The use of overlapping synthetic peptides from this region 
demonstrated that the amino acid sequence representative of residues 1553-1558 were the 
main contributors of the inhibition of S13A on prothrombinase. This was confirmed by 
the fact that N6A had the same inhibition profile as S13A. Further, when the charged 
residues present within this region were exchanged for amino acids lacking charge (i.e. 
tyrosine residues exchanged for phenylalanine residues), in essence removal of the charge, 
the ability of N6A to inhibit prothrombinase function was lost, suggesting the 
involvement of the two tyrosine residues present at positions 1554 and 1555. While all of 
the peptide studies generated consistent results, the major weakness of the peptide portion 
of the present study is the specificity of peptides and whether the observed inhibition is 
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due to the weakened interaction of the highly specific fVa/fXa association as opposed to 
a nonspecific inhibition.   
To ascertain whether the indicated region from the peptide study was involved in 
the fVa mediated assembly of the prothrombinase complex a recombinant study 
employing a fV mutant deleting the indicated region was undertaken. The rfVa
dS13A
 
mutant was directly assayed for its ability to recognize fXa and the measurements of the 
interaction for the rfVa
dS13A
 with fXa demonstrated a greatly weakened association 
between the two proteins when compared to the rfVa
WT
/fXa interaction. This strongly 
suggests that the loss of the ability of the rfVa
dS13A
 molecule to recognize fXa with the 
same affinity as rfVa
WT
 is due to the loss of a major binding site present within the 
deleted region. When fXa is fully saturated with the rfVa
dS13A
 mutant a reduced Kcat is 
observed, this is consistent with a previously observed phenomenon using recombinant 
fVa mutants with a diminished ability to recognize fXa (23). As previously shown, the 
ability of fVa to optimally promote catalysis through fXa is dependent on the proper 
association between several points of contact between the two proteins and the lowered 
Kcat generated from prothrombinase assembled with the rfVa
dS13A
 mutant is consistent 
with this previously observed phenomenon (23).  
A major concern for the recombinant portion of this study is the accuracy of the 
determined concentration of the rfVa
dS13A
 molecule. If the determined concentration of 
the rfVa
dS13A
 mutant is elevated over the true concentration, then the determined KD 
would also be elevated and the generated results would be skewed. However, this would 
not account for the decreased ability of the rfVa
dS13A
 cofactor to promote the generation 
of thrombin when assembled into the prothrombinase complex, since the apparent KD 
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values enabled the determination of the concentration of the cofactor molecule needed to 
fully saturate fXa. Another concern with the recombinant portion of this study is a 
concern that any recombinant study has being the possibility that the induced mutation 
had a detrimental effect on the confirmation of the protein. Though rfVa
dS13A
 generated a 
light chain upon thrombin incubation comparable to that of the rfVa
WT
, a persistent 
activation fragment around 220,000kDa persisted and appeared to be resistant to 
thrombin cleavage. However, even though detectable concentrations of the light chain 
were always generated, the function of the rfVa
dS13A
 cofactor molecule could not be 
restored by increasing the concentration, suggesting that the decreased cofactor activity 
observed in the rfVa
dS13A
 was due to the loss of an interactive site for fXa.  
Since the characterization of the recombinant deletion molecule displayed an 
impaired function resulting from a weakened interaction with fXa, the hypothesis that a 
major binding site is present within the deleted portion of rfVa
dS13A
 is greatly 
strengthened. Coupled with the fact that both the peptide study and the recombinant study 
suggested the same region of the light chain of fVa was involved in the recognition of 
fXa also strongly supports the hypothesis. The amino-terminal portion of the light chain 
of fVa has an extremely conserved sequence across species with the sequence of the 13 
amino acids represented by S13A showing strong conservation. The high degree of 
conservation of this region suggests an important function present within this region and 
coupled with previous observations of the light chains involvement in the recognition of 
fXa, further strengthens the hypothesis that this region is involved in recognition of fXa. 
 In conclusion, the present study strongly suggests that the amino-terminal portion 
of the light chain of fVa is involved in the association with fXa and that the loss of this 
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interactive site results in a decreased ability of prothrombinase to generate thrombin in an 
efficient manner. Further, the involvement of amino acid residues 1546-1558 in the 
recognition of fXa is a prerequisite for the association of fVa with fXa and consequently 
these residues are necessary for proper prothrombinase assembly. 
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CHAPTER V 
OVERALL CONCLUSIONS 
5.1 CONCLUSION 
 The assembly of prothrombinase is crucial for the function of prothrombinase; the 
two events are interconnected and cannot be separated from each other. The contribution 
of fVa to the assembly/function of the prothrombinase complex is essential; since it is 
involved in recognizing all of the components of prothrombinase. Hence fVa can be 
considered the driving force behind prothrombinase complex formation and function. The 
interaction of fVa with all of the components of prothrombinase is the accelerating event 
in the activation of prothrombin which results in the rapid generation of thrombin through 
formation of the enzymatic intermediate, meizothrombin (1,2). Prothrombinase consists 
of an assembly of the two activated clotting factors (i.e., fXa and fVa) in the presence of 
divalent metal ions on an activated platelet surface (3). The association between fVa and 
fXa has been shown to involve two distal portions of fVa, involving residues present 
within the A2 domain of the heavy chain and A3 domain of the light chain (4).   
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 Previous studies have demonstrated that the association between fVa and fXa is 
partially mediated through the region encompassing residues 307-348 present within the 
heavy chain of fVa (5). Presently we have shown that this interaction between the A2 
domain of the heavy chain of fVa and fXa is mediated through four distinct amino acid 
residues; Asp
323
, Tyr
324
, Asp
330
 and Val
331
. Recombinant technologies were used to 
induce site-specific mutations present within these residues to assay their contribution to 
the activity of prothrombinase. The data demonstrated that the removal of either binding 
sites present on fVa (i.e., 
323
DY
324
 or 
330
DV
331
) for fXa resulted in a decreased KD for the 
interaction between the two proteins with little effect on the Kcat for prothrombinase 
assembled with fVa mutated at either of the two binding sites. When the induced 
mutations for both of the discrete binding sites present within the heavy chain of fVa 
were combined into the same recombinant protein, a normal Kcat value could not be 
restored when assembled into prothrombinase. This demonstrates that the optimal 
interaction between fVa and fXa is a prerequisite for the catalytic efficiency normally 
displayed by prothrombinase (6,7). 
 It has been demonstrated on several occasions that the interaction of fVa with fXa 
involves the light chain of the activated cofactor (8-11). Screening overlapping synthetic 
peptides representative of sequences present within the light chain of fVa for their ability 
to inhibit the prothrombinase catalyzed activation of prothrombin demonstrated that the 
peptide representative of the first thirteen amino acids present at the beginning of the 
light chain of fVa was the strongest inhibitor of prothrombinase. The recombinant follow 
up study demonstrated that the removal of this region from the light chain of fVa resulted 
in a diminished association with fXa and when the deletion protein was assembled into 
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prothrombinase, the enzymatic complex displayed a 50% reduction in its ability to 
activate prothrombin. Demonstrating again that for prothrombinase to achieve optimal 
catalytic efficiency the unhindered interaction between fVa and fXa is necessary.              
 Prothrombinase recognizes prothrombin in a fashion different than membrane-
bound fXa. Several studies have demonstrated that the carboxyl-terminal portion of the 
heavy chain of fVa is involved in the recognition of prothrombin by prothrombinase (12-
15). We have previously shown that residues 
695
DYDYQ
699
 from the heavy chain of fVa 
are crucial for optimal prothrombinase activity and have also demonstrated that a 
synthetic peptide representative of these residues strongly inhibited thrombin generation 
by prothrombinase in a manner consistent with substrate depletion (16). Presently we 
have explored the ability of lipid-bound fXa and prothrombinase to activate prothrombin 
and derivatives of prothrombin in the presence of the pentapeptide D5Q. We have seen 
the association of D5Q with prothrombin causes a switch in the pathway to thrombin 
generation by prothrombinase and greatly delays thrombin generation by lipid-bound fXa 
by inhibiting the activation of the prethrombin 2/fragment 1·2 intermediate (17). In both 
cases the interaction of D5Q with prothrombin specifically inhibited the activating 
cleavage at Arg
320
 and resulted in a greatly delayed generation of thrombin. Interestingly, 
D5Q was incapable of significantly inhibiting the activation of any of the other 
prothrombin derived substrates tested throughout this study suggesting the selective 
nature of the observed inhibition (18).       
 The optimal catalytic efficiency of prothrombinase can only be realized when fVa 
is properly associated with fXa. This is because the accelerated enzymatic capability of 
fXa is dependent on the association with fVa through residues present in both the heavy 
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and light chains of fVa. We have shown that the association between fVa and fXa involve 
residues 
323
DY
324 
and 
330
DV
331
 from the A2 domain of the heavy chain of fVa and also 
involves amino acids present within residues 1546 through 1558 of the A3 domain (6). 
While the residues 
323
DY
324 
and 
330
DV
331
 and the region from residues 1546 through 1558 
are important for proper assembly of prothrombinase, the carboxyl terminal portion of the 
heavy chain of fVa is necessary for prothrombinase to properly recognize prothrombin 
(16). It has been demonstrated that a loss of the carboxyl terminal portion of the heavy 
chain of fVa results in a cofactor with reduced activity when assembled into 
prothrombinase (19). Further, a pentapeptide from this region, DYDYQ, greatly inhibits 
the activation of prothrombin by prothrombinase in a fashion consistent with substrate 
depletion, suggesting that the sequence 
695
DYDYQ
699
 directly interacts with the substrate, 
prothrombin (16).    
 Since all of the above mentioned regions are crucial for prothrombinase assembly 
and consequently prothrombinase function, they represent possible targets for inhibiting 
prothrombinase. Prothrombinase function may be stopped through interrupting its 
assembly, since prothrombinase assembly is a prerequisite for its proper function. 
Through defining major points of interaction between the components of prothrombinase 
novel therapeutic targets are defined that can specifically interfere with the assembly of 
prothrombinase. Therefore, inhibitory synthetic peptides derived from amino acid 
sequences present within fVa, not only illuminate the molecular functions of 
prothrombinase but may represent a backbone on which to design potential therapeutic 
agents which will specifically target prothrombinase.  
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